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SUMMARY 
 
Screening of antibody (Ab) libraries by direct display on the surface of E. coli cells is 
hampered by the presence of the outer membrane (OM). In this work, we 
demonstrate that the native β-domains of EhaA autotransporter and Intimin, two 
proteins from enterohemorrhagic E. coli O157:H7 (EHEC) with opposite topologies 
in the OM, are effective systems for the display of immune libraries of single domain 
Abs (sdAbs) from camelids (nanobodies or VHH) on the surface of E. coli K-12 cells 
and for the selection of high affinity sdAbs using magnetic cell sorting (MACS). We 
analyzed the capacity of EhaA and Intimin β-domains to display individual sdAbs 
and sdAb libraries obtained after immunization of camelids with different proteins of 
biomedical interest, i.e. the extracellular domain of the translocated intimin receptor 
from EHEC (TirMEHEC), human fibrinogen (Fib) and A431 cells displaying human 
epidermal growth factor receptor (EGFR). We demonstrated that both systems 
displayed functional sdAbs on the surface of E. coli cells with little proteolysis and 
cellular toxicity, although E. coli cells displaying sdAbs with the β-domain of Intimin 
showed higher antigen-binding capacity. The sdAb libraries against TirMEHEC and 
Fib cloned in both E. coli display platforms were screened for antigen binding 
clones by MACS using purified biotinylated antigen. High affinity binders were 
selected by both display systems, although more efficiently with the Intimin β-
domain. The specificity of the selected clones against their respective antigen was 
demonstrated by flow cytometry of E. coli cells, along with ELISA and surface 
plasmon resonance with purified sdAbs. In addition, we employed the E. coli cell 
display systems to provide an estimation of the affinity of the selected sdAb by flow 
cytometry analysis under equilibrium conditions. Further, we used the β-domain of 
Intimin to display a sdAb library against human EGFR and developed a method for 
the direct selection of this sdAb library on cells. Bacteria displaying the anti-EGFR 
sdAb immune library were subjected to consecutive rounds of selection on EGFR-
negative cells (i.e. murine fibroblast cell line, 3T3 2.2) and EGFR-positive cells 
HER14 (i.e. 3T3 2.2 transfected cells expressing human EGFR) to enrich for EGFR-
specific binding clones. EGFR-specific clones that bound HER14 cells and not 3T3 
2.2 cells were identified and their specific binding to EGFR confirmed by flow 
   17 
cytometry analysis using biotinylated EGFR-Fc fusion. In addition, we used E. coli 
display to characterize the affinity and binding of these sdAbs to EGFR-Fc in the 
presence or absence of an excess of EGF, a natural ligand of EGFR. Our data 
demonstrates that E. coli display allows the selection of sdAbs against relevant 
tumor-associated antigens from libraries generated by cell immunization and 
performance of direct selection on tumor cells without the need for purified 
antigens. 
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PRESENTACIÓN 
 
Introducción 
Los anticuerpos (Abs, del ingles “antibodies”) o inmunoglobulinas (Igs) son 
proteinas globulares plasmáticas producidas por los linfocitos B y utilizadas por el 
sistema inmune para identificar moléculas ajenas al organismo llamadas antígenos 
(Ags). Los anticuerpos convencionales están formados por dos cadenas pesadas 
(H, del ingles “heavy”) y dos cadenas ligeras (L, del inglés “light”) idénticas. Cada 
una de estas cadenas se componen de regiones variables (VH y VL) y regiones 
constantes (CH y CL). La especificidad de cada anticuerpo se encuentra definida 
por las regiones determinantes de complementariedad (CDRs, del inglés 
“complementarity determining regions”) localizadas en las regiones VH y VL, 
mientras que la región Fc media funciones efectoras. Los Abs han sido 
ampliamente utilizados tanto para detectar antígenos así como en terapias. Los 
Abs convencionales monoclonales (mAbs) son producidos mediante hibridomas 
utilizando ratones, pero estos mAbs producen una respuesta inmune no desada en 
humanos lo que restringe su potencial terapéutico. Por ello, se han desarrollado 
estrategias alternativas para producir mAbs completamente humanos como son la 
producción de mAbs en animales transgénicos con loci de Ig humanos y la 
utilización de genotecas de Abs que se expresan en la superficie de bacteriófagos 
de E. coli y de células de levadura. Además, se han dedicado grandes esfuerzos 
en el desarrollo de reactivos de tipo anticuerpo basados en fragmentos de estos. 
Los fragmentos de Ab más comúnmente utilizados incluyen los fragmentos Fv 
monocadena  (scFv, consisten en los dominios VH y VL unidos con un conector 
peptídico), los fragmentos Fab (generados mediante la fusión del dominio C con 
dominios V), y los anticuerpos monodominio  (sdAbs, del inglés “single domain 
antibodies”) que son fragmentos de pequeño tamaño (peso molecular de 
aproximandamente 12-15 kDa), totalmente capaces de unirse a antígenos y 
formados por un único dominio variable (V). El tipo más común de sdAbs, también 
conocidos como “nanobodies” o VHHs, es generado a partir de dominios VH de 
anticuerpos que poseen únicamente cadenas pesadas (HCAbs, del inglés “heavy-
chain-only antibodies”) y que se encuentran de forma natural en camélidos (llamas, 
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dromedarios, etc.). Su tamaño pequeño, sus propiedades biofísicas y su 
capacidad de unión a los antígenos hacen de los “nanobodies” unas moléculas 
muy atractivas para múltiples aplicaciones. Además, las secuencias de sdAbs son 
muy similares a las secuencias de los dominios VH3 humanos, por lo que pueden 
ser utilizados en terapia y en diagnóstico in vivo con un riesgo menor de efectos 
adversos. 
 
Las genotecas de anticuerpos pueden ser obtenidas después de una inmunización 
del organismo donante con el antígeno de interés (en inglés “immune libraries”), a 
partir de donantes no inmunizados (colecciones naïve) o generadas artificialmente 
mediante el ensamblaje in vitro de los genes V (colecciones sintéticas). La técnica 
de la presentación de anticuerpos en fagos (en inglés “phage display”) es el 
método más común de presentación y selección de anticuerpos. Una de las 
principales ventajas del “phage display” es la posibilidad de realizar colecciones 
de gran tamaño (hasta 1010 clones) debido a la alta eficiencia del clonaje de genes 
V en vectores fágicos en E. coli.  Sin embargo, este sistema tiene algunas 
limitaciones como la alta probabilidad de aislar clones no específicos de unión al 
antígeno por la tendencia de los fagos de adherirse inespecíficamente, la 
necesidad de infectar bacterias para generar partículas fago-Ab y la imposibilidad 
de analizar los clones obtenidos mediante citometría de flujo (FACS, del inglés 
“fluorescence activated cell sorting”) debido al pequeño tamaño de las partículas 
víricas. Un sistema alternativo utiliza células de levadura para la exposición de 
anticuerpos en la superficie celular y su posterior selección. Entre las ventajas de 
este método se encuentran la posibilidad de utilizar la técnica de citometría de 
flujo para la selección y caracterización de los anticuerpos aislados, la capacidad 
de las levaduras de realizar modificaciones post-traduccionales que pueden ser 
relevantes para la funcionalidad de los anticuerpos y la posibilidad de determinar 
directamente la afinidad de los anticuerpos expuestos. Sin embargo, las levaduras 
tienen menor eficiencia de transformación y tasa de crecimiento en comparación 
con E. coli. 
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La presentación de anticuerpos en E. coli ofrece una alternativa atractiva a los 
sistemas de exposición de anticuerpos anteriormente descritos, ya que se 
obtienen altas eficiencias de transformación, tasas de crecimiento elevadas y la 
posibilidad de utilizar métodos de citometría de flujo para la selección y 
caracterización de los clones de anticuerpos aislados. A pesar de todas estas 
ventajas, la presencia de la membrana externa (OM, del inglés “outer membrane”) 
en E. coli  interfiere con la correcta exposición del anticuerpo y ha dificultado el 
desarrollo de sistemas eficientes de presentación de anticuerpos en este 
microorganismo. Estudios realizados anteriormente en nuestro laboratorio con 
modelos de VHH demostraron que los dominios β de anclaje a la OM pertenecientes 
al autotransportador EhaA y de la intimina de la cepa enterohemorrágica E. coli 
O157:H7 (EHEC) son sistemas muy prometedores para la exposición de sdAbs en 
la superficie de la cepa E. coli K-12. 
 
Objetivos 
Los objetivos del presente trabajo son: 
1) Evaluar y comparar los dominios β de EhaA e intimina como sistemas de 
exposición de sdAbs funcionales en la superficie de E. coli. 
2) Utilizar los sistemas de presentación de anticuerpos basados en los 
dominios β de EhaA e intimina para la expresión de genotecas de sdAbs de 
animales inmunizados y posterior selección de clones con alta afinidad por 
antígenos proteicos de origen bacteriano y humano. 
3) Caracterizar los sdAbs seleccionados mediante la técnica de presentación 
en la superficie E. coli, determinar su afinidad de unión y especificidad 
mediante citometría de flujo, y comparar los resultados con aquellos 
obtenidos con tecnologías bioquímicas estándar como el ensayo por 
inmunoabsorción ligado a enzimas (ELISA, del inglés “enzyme-linked 
immunosorbent assay”) y la resonancia de plasmones de superficie (SPR, 
del inglés “surface plasmon resonance”). 
4) Utilizar la plataforma de presentación de anticuerpos en E. coli para la 
selección directa de sdAbs utilizando células tumorales vivas que expresan 
un antígeno tumoral relevante en su superficie, como el receptor de factor 
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de crecimiento  epidérmico (EGFR, del  inglés “epidermal growth factor 
receptor“). 
Resultados 
En primer lugar analizamos la capacidad de los dominios β de EhaA e intimina 
(pertenecientes a EHEC) para exponer sdAbs individuales y colecciones post-
inmunización de sdAbs originados a partir de VHHs de camellos dirigidos contra el 
dominio extracelular del receptor translocado de intimina de EHEC (TirMEHEC) y 
contra fibrinógeno humano (Fib). Demostramos que ambos sistemas pueden ser 
utilizados para exponer sdAbs funcionales en la superficie de células de E. coli con 
poca proteolisis y toxicidad celular, aunque las células de E. coli que exponían los 
sdAbs con el dominio β de intimina mostraron una mayor capacidad de unión al 
antígeno. Se examinaron ambos tipos de sistemas de presentación de E. coli con 
colecciones de sdAbs para buscar clones específicos de antígeno mediante 
separación magnética de células (MACS, del inglés “magnetic cell sorting”) 
utilizando antígenos biotinilados. Se aislaron clones con alta afinidad por sus 
respectivos antígenos utilizando los dos tipos de presentación de sdAbs, aunque 
el proceso fue más eficiente con el sistema del dominio β de intimina.  Se 
determinó la especificidad de los clones seleccionados contra TirMEHEC y Fib 
mediante análisis por citometría de flujo de células de E. coli, y con las técnicas 
ELISA y SPR utilizando sdAbs purificados. A continuación, utilizamos los sistemas 
de presentación de sdAbs en células de E. coli para estimar la afinidad de los 
sdAbs seleccionados mediante análisis de citometría de flujo en condiciones de 
equilibrio. 
 
Adicionalmente, la plataforma de presentación de sdAbs con el dominio β de 
intimina fue empleada para la selección de VHHs a partir de una genoteca inmune 
generada contra EGFR mediante la inmunización de llamas (Lama glama) con la 
línea celular humana de origen tumoral A431. Las bacterias que presentaban la 
colección de sdAbs en su superficie fueron sometidas a rondas sucesivas de 
selección sobre células negativas para EGFR (línea celular fibroblástica murina, 
NIH-3T3 2.2) y células positivas para EGFR, como HER14 (células NIH-3T3 2.2 
transfectadas que expresan EGFR humano) para el enriquecimiento de clones que 
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unían específicamente EGFR. Se identificaron clones EGFR-específicos que se 
unían a células HER14 pero no a células NIH-3T3 2.2, y se confirmó su capacidad 
de unión específica a EGFR a través de análisis por citometría de flujo utilizando 
fusiones biotiniladas EGFR-Fc. Además, utilizamos el sistema de presentación de 
sdAbs en E. coli para determinar la afinidad de la unión de estos sdAbs a EGFR-Fc 
en presencia de un exceso de EGF, el ligando natural de EGFR. Nuestros datos 
demuestran que el sistema de presentación de sdAbs en E. coli permite la 
selección de sAbs contra antígenos relevantes asociados a tumores a partir de 
colecciones generadas mediante inmunización con células. Esta selección se 
puede realizar directamente sobre células tumorales sin la necesidad de utilizar el 
antígeno purificado. 
 
Por último, desarrollamos un método alternativo para la producción y purificación 
de sdAbs del periplasma de E. coli basado en fusiones de sdAbs con la proteína 
de unión a maltosa (MBP, del inglés “maltose binding protein”) en el extremo N- 
terminal y con una cola de histidinas (His6) en el extremo C-terminal (MBP-VHH-
His6). Se produjeron consistentemente niveles elevados de fusiones solubles 
MBP-VHH-His6 (>12 mg/L de cultivo inducido en matraces) en el periplasma de E. 
coli HM140, una cepa que carece de varias proteasas periplásmicas. Se 
recuperaron fusiones MBP-VHH-His6 de gran pureza y fusiones libres VHH-His6 
(después de una proteolisis especíifica de sitio de las fusiones), tras realizar dos 
procesos de cromatografía de afinidad a amilosa y a metales. Se determinó la 
naturaleza monomérica de los VHH-His6 mediante cromatografía de filtración en gel. 
También demostramos mediante ELISA que las fusiones monoméricas VHH-His6 y 
MBP-VHH-His6 retenían su capacidad de unión al antígeno y su especificidad, 
facilitando su utilización directa en ensayos de reconocimiento de antígeno. 
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1. Antibodies and Recombinant antibody fragments 
1.1 Antibodies and their application in human therapy 
Antibodies (Abs) or Immunoglobulins (Igs) are proteins that play a very important 
role in the immune system of humans and animals. These proteins are produced by 
B-lymphocytes and are deployed by the immune system to identify and target 
foreign or non-self molecules (Nelson et al., 2000; Ohlin and Zouali, 2003). Every 
human being has on an average, about one to two billion different Abs continuously 
flowing through his or her bloodstream, patrolling and fighting infections or 
diseases. The basic structure of an Ab consists of two identical light and heavy 
chains, linked by disulfide bonds. Each heavy and light chain contains a variable 
sequence (VH and VL respectively) in the amino terminal and constant sequences 
(CH and CL) in the remaining portion of the chain. Variability of the Abs, which 
accounts for their different specificities, is located in the VH and VL, clustered in 
several hypervariable regions: the complementarity determining regions (CDRs). The 
CDRs determine the specificity of the Ab for its cognate antigen, thus allowing the 
detection of millions of different antigens present in nature. The Fc region of the Ab, 
on the other hand, is essential for mediating effector functions like antibody-
dependent cytotoxicity (ADCC), Ab-dependent cellular phagocytosis, complement 
mediated lysis and regulation of cell activation or proliferation. Thus, the structure of 
the Ab (Figure 1A) determines its binding specificity and biological activity (Birch 
and Racher, 2006). 
 
 
Figure 1. Structure of conventional antibodies and antibody derived fragments. 
(A) Structure of conventional IgGs with heavy chain (H) and light (L) chains indicating the 
crystallizable fragment (Fc) region and antigen binding sites or CDRs. (B) Common antibody-derived 
antigen-binding fragments: single-chain Fv (scFv) and Fab are shown along with single domain VH 
and VL fragments. 
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Abs have been widely used for antigen detection as well as in therapeutics, and 
their specificity combined with low toxicity make them promising pharmaceutical 
molecules (Berger et al., 2002). At present, they comprise the second-largest 
category of biological medicines in clinical development, after vaccines (Seymour, 
2004). However, therapeutic use of antibodies was initially limited by 
methodological constraints in raising them. Conventional monoclonal antibodies 
(mAbs) were commonly obtained by immunization of experimental animals, usually 
mice, with target antigens. Fusions of B-cells from immunized animals with 
myeloma cell lines produced hybridomas able to grow in culture and that could be 
screened for specific Ab-producing clones (Kohler and Milstein, 1975). Although 
well established, this technology is laborious and biased by the immune system of 
the experimental animal, which limits the ability to obtain high affinity Abs against 
conserved mammalian proteins of interest. Additionally, the heterologous character 
of these murine mAbs make them immunogenic to humans and elicit “Human anti-
mouse antibody” (HAMA) response, which restricts their use in therapy (Schroff et 
al., 1985). Hence, human antibodies are of particular interest due to a lower 
immunogenic response. Human hybridomas were initially evaluated, but were found 
to be unstable, difficult to prepare and secreted low levels of mAbs of the IgM class 
with low affinities. Two other approaches to produce fully human mAbs from phage 
display libraries (McCafferty et al., 1990) or transgenic animals (Bruggemann et al., 
1991) have been possible since the early 1990s. At present, about 30 mAbs 
produced by these methods have already been approved by the Food and Drug 
Administration (FDA) for therapy (Scott et al., 2012; Pandey and Mahadevan, 2014). 
 
In order to be successful as therapeutic molecules, Abs need to have properties like 
high binding affinities, reduced immunogenicity, increased half-life in the human 
body and the ability to adequately recruit human effector functions. These factors 
combined with the knowledge that the segmented structure of the Ab molecule 
allows functional domains (carrying antigen-binding or effector functions) to be 
exchanged, has led to the construction of either, chimeric antibodies i.e. by 
coupling of the animal antigen-binding variable (V) region with the human constant 
domains or humanized antibodies, i.e. by grafting of the CDRs derived from murine 
antibodies with desired specificity onto carefully chosen human VH and VL 
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frameworks (FRs) (Figure 2). Six chimeric, fifteen humanized and ten fully human 
mAbs are currently on the market, including some Fabs.  
 
 
Figure 2. Chimeric and humanized antibodies. 
 (From left to right) A murine antibody (blue), a human antibody (yellow), a chimeric antibody (with 
murine variable domains and human constant domains) and a humanized antibody (a human 
antibody with CDRs of murine origin). 
 
Despite the general success of whole IgGs in therapy, the large size of these 
molecules leads to practical drawbacks such as lower tumor or tissue penetration, 
long serum half-life and subsequent low tumor-to-blood ratio; all or some of which 
makes difficult their use in applications like radioimmunotherapy and in vivo 
diagnostic imaging. Secondly, conventional mAbs have specificity for a single 
antigen epitope, and since most diseases are multifactorial, involving multiple 
ligands, receptors and signalling cascades, it would be beneficial to have bivalent or 
multivalent molecules that could target two or more epitopes. Lastly, the structural 
properties of a full-length Ab require sophisticated folding mechanisms as well as 
an oxidizing environment for the generation of disulfide bonds; since most 
traditional expression hosts do not provide such an environment, the industrial 
production of full length IgGs is mostly restricted to mammalian cells leading to 
slow production at high cost. 
 
To circumvent these limitations of mAbs, substantial efforts have gone in to the 
development of the next wave of therapeutic and diagnostic reagents based on Ab 
fragments. In many cases, efforts have been made to improve or even delete some 
characteristics. For example, to achieve better tumor penetration or a better tumor-
to-blood ratio for visualizing metastases, it would be preferable to have a relatively 
small Ab fragment with a fairly short half-life. On the other hand, the molecule 
should not be too small, in order to avoid rapid clearance from the body 
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immediately after its application. In addition, it would be advantageous in certain 
applications to improve the effector functions, while in others, such as in 
radioimmunotherapy or in vivo imaging, it is imperative that Fc mediated cellular 
effects and prolonged half life do not exist. 
1.2 Recombinant fragments from conventional antibodies 
It is striking to note that the use of Ab fragments started as early as in the late 1950s 
after the pioneering work of Porter (Porter, 1958), which made possible the better 
understanding of the topology of  IgGs  and the functions associated with the 
different Ab fragments obtained after controlled proteolytic cleavage. Conversion of 
monovalent Ab fragments into multivalent formats increases functional affinity; 
decreases dissociation rates when bound to cell-surface receptors or polyvalent 
antigens and enhances biodistribution (Holliger and Hudson, 2005). These 
molecules are particularly useful in applications, where epitope binding is sufficient 
for the desired effect, including therapeutic applications such as virus neutralization 
or receptor blocking. The smallest antigen-binding fragment of IgGs maintaining its 
complete antigen-binding site is the Fv fragment, which consists only of V regions. 
However, the expression of an individual variable domain of a FV, either VH or VL 
domain, exposes a large hydrophobic side to the aqueous environment that render 
these types of molecules difficult to handle. This shortcoming is overcome by 
introducing a soluble and flexible amino acid peptide linker linking the VH and VL 
domains, to form a scFv fragment, which leads to stabilization of the molecule (Bird 
et al., 1988). Also common is to add the constant (C) domains to the V regions to 
obtain a Fab fragment.  
 
Till date, scFvs and Fabs are the most widely used Ab fragments produced in 
bacteria (Figure 1B). Other formats that have been produced in prokaryotic and 
eukaryotic cells include disulfide-bond stabilized scFvs (ds-scFv) (Schmiedl et al., 
2000), single chain Fab fragments (scFab) (Hust et al., 2007) which combines 
properties of scFv and Fab, as well as di- and multimeric Ab formats like dia-, tria-, 
tetra-bodies (Hudson and Kortt, 1999; Carter, 2006), minibodies (Hu et al., 1996; 
Holliger and Hudson, 2005) or trimerbodies (Cuesta et al., 2012). 
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1.3 Heavy-chain only antibodies, single domain antibodies and nanobodies 
In the early 1990s, a novel type of Abs lacking light chains was discovered in the 
serum of camelids (Hamers-Casterman et al., 1993). This unique class of heavy 
chain only antibodies (HCAbs) are apparently the outcome of recent adaptive 
changes occurring in conventional antibodies within the Camelidae lineage (Flajnik 
et al., 2011) and play a role in the immune response of these animals. A second 
type of HCAbs is found in sharks (Greenberg et al., 1995). The structure of camelid 
HCAbs is illustrated in Figure 3A. The homodimeric HCAbs lack light chains and 
thus antigen recognition is possible solely through the variable domain of the heavy 
chain, referred to as VHH for VH of HCAbs. The recombinant expression of VHHs 
yields a soluble single domain Ab (sdAb) fragment with dimensions of 2-4 nm, and 
has been referred to as Nanobody (Nb). Nbs have a molecular weight of ∼15 kDa, 
which is at least half the size of the intact antigen-binding site of a conventional Ab 
(i.e, the VH-VL pair) and are the smallest, intact antigen-binding fragments derived 
from a functional immunoglobulin (Figure 3A and 3B).  
 
 
Figure 3. Structure of camelid heavy chain only antibodies and nanobodies. 
(A) Schematic representation of a heavy chain only antibody with the structure of the VHH domain 
highlighted. The CDRs are labelled in different colours: CDR1 in yellow, CDR2 in green, CDR3 in blue 
and the framework regions (FR) are indicated in red. (B) The linear structural diagram of a VHH 
domain. CDRs are labelled with the same colour scheme as in part A and also the disufide bonds in 
the molecule, i.e. canonical and additional are illustrated. 
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These molecules have naturally acquired important adaptations to remain soluble 
and functional in the absence of the associated light chain variable domain. Further, 
they have evolved long CDRs with novel conformations for antigen recognition, 
subtle amino acid adaptations including substitutions of conserved hydrophobic 
residues in classical VHs (V37, G44, L45, and F47/W47) for more hydrophilic amino 
acids (Y37/F37; E44/Q44; R45/C45; G47/R47/L47/S47) (Muyldermans, 2013), that 
confer them strict monomeric behaviour, reversible folding properties, resistance to 
proteolysis and thermal degradation when compared with the VH from conventional 
antibodies (van der Linden et al., 1999; Dumoulin et al., 2002). Furthermore, VHHs 
often contain, besides the canonical disulfide bond of Ig domains, an extra-disulfide 
bond connecting CDR3 and CDR1 (in camels) or CDR3 with CDR2 (in llamas) that 
assist in stabilizing the conformation of these CDRs and the overall stability of the 
domain (Figure 3B) (Govaert et al., 2012). 
 
The small size and long CDRs of VHHs allow them to recognize epitopes located in 
clefts and protein cavities (Figure 4A) such as active sites of enzymes, conserved 
inner regions of surface proteins from pathogens, which are frequently less 
accessible to large molecules and conventional Abs (Desmyter et al., 1996; 
Lauwereys et al., 1998; Stijlemans et al., 2004). In addition, they share high 
sequence identity with human VH sequences of family 3 (Figure 4B), which opens 
the possibility of their use in human therapy and in in vivo diagnosis (Wesolowski et 
al., 2009; Vaneycken et al., 2011). Apart from these advantages, the recombinant 
expression of VHHs turned out to be favourable as well, as is validated in various 
expression systems. They are preferentially expressed in E. coli, where they can be 
produced economically as soluble and non-aggregating recombinant proteins with 
an incorporated histidine tag for easy purification (Arbabi-Ghahroudi et al., 2005), 
though the levels of soluble VHHs produced are highly variable (Alvarez-Rueda et al., 
2007). Higher production levels of VHH can be obtained using high-density cultures 
in yeast systems like Pichia pastoris and Saccharomyces cerevisiae (Frenken et al., 
2000) or in tobacco plants (Rajabi-Memari et al., 2006). 
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Figure 4. Comparison between conventional VH/VL and VHH antibody fragments. 
(A) Three-dimensional structure of chicken lysozyme recognized by an scFv (VH/VL domains) (left; 
PDB code 1mlc) or by a VHH domain of camelid HCAb (right; PDB code 1mel). The CDRs of VH, VL 
and VHHs are shown in different colors (CDR1 in orange, CDR2 in green, CDR3 in cyan). The long 
CDR3 loop of the VHH protrudes as a finger-like structure toward an epitope located in the cavity of 
the active site of lysozyme (right), whereas the flat VH/VL paratope binds to an epitope located at the 
exposed surface of lysozyme (left).(B) Cartoon showing the polypeptide chains of conventional VH 
and camelid VHHs, indicating the amino acids of framework region 2 of classical VHs (V37, G44, L45, 
W47) that are substituted by more hydrophilic amino acids (e.g. Y37, E44, R45, G47) in VHHs. Other 
distinct features shown are the different length of CDR1 and CDR3 in VHs and VHHs, the presence of 
the conserved canonical disulfide bond between residues C22 and C92, and the extra-disulfide bond 
between Cys residues of CDR1 and CDR3 in VHHs. 
 
Because of their single domain nature, VHHs, offer several advantages for 
biotechnological applications. Libraries of VHHs from immunized camels and llamas 
can be generated through a straightforward cloning procedure in various display 
systems and selected using antigen immobilized in plates or on cells (Arbabi 
Ghahroudi et al., 1997; Roovers et al., 2007; Ahmadvand et al., 2009; Ryckaert et 
al., 2010; Fleetwood et al., 2012). VHHs within these libraries retain full functional 
diversity resulting in isolation of high-affinity antigen-binding clones. The short 
serum-life due to renal clearance may limit the efficacy of VHHs in therapeutic 
applications. Therefore, bispecific VHHs recognizing long-lived serum proteins like 
albumin or immunoglobulins and the therapeutic target have been generated, thus 
resulting in increased half-lives (Tijink et al., 2008; Vosjan et al., 2012). The binding 
and stability properties portrayed by natural VHHs has led to considerable interest in 
the development of human sdAbs based on human VH (or VL) sequences that could 
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mimic natural VHHs. Murine VH sdAbs against lysozyme were isolated from phage 
display in E. coli before the discovery of natural HCAbs in camels (Ward et al., 
1989). However, most VH sequences from conventional Abs tend to aggregate in 
solution and show low affinity for antigens. Introduction of ‘camel’ mutations G44E, 
L45R, and W47G, in a human VH3 sequence significantly increased its solubility 
(Davies and Riechmann, 1994). Human VH clones with low tendency to aggregate 
were isolated by repeated cycles of heating and cooling of phages with displayed 
VH sequences (Jespers et al., 2004). Based on these findings, synthetic libraries of 
human VHs have been developed by randomizing CDRs in ‘camelized’ and/or 
selected human VH sequences and used for isolation of functional sdAbs with 
nanomolar affinity (Davies and Riechmann, 1994; Dumoulin et al., 2002; Holt et al., 
2008; Arbabi-Ghahroudi et al., 2009). sdAbs based on human VL domains have also 
been reported and expressed in E. coli. These include VL domains from 
conventional IgGs and naive scFv libraries (Colby et al., 2004; Martsev et al., 2004; 
Cossins et al., 2007; Schiefner et al., 2011) and sdAbs isolated from synthetic 
libraries (van den Beucken et al., 2001; Holt et al., 2008) 
2. Selection of antibodies from libraries using surface display. 
2.1 Libraries of antibody genes 
Combinatorial Ab engineering or directed evolution is an efficient approach for 
generation of Abs with new or improved properties (e.g. affinity) and is based on the 
generation of molecular libraries containing up to hundreds of billions of different 
Abs, from which specific binders might be isolated by display and high-throughput 
screenings or selections. One of the considerations to be taken in to account when 
constructing a library is the size. A larger library covers a larger part of the 
theoretical repertoire and results in a higher probability of containing and isolating 
high-affinity clones. This correlation has been supported by experimental data 
generated in different studies (Bradbury and Marks, 2004). Equally important is that 
the Abs in the library are functional. Ab libraries can be classified into three main 
types, namely immune, naïve and synthetic libraries. 
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Immune libraries are generated from the V genes of B-cells isolated from the lymph 
nodes, spleen, or peripheral blood of immunized animals or human donors 
(Clackson et al., 1991) and takes advantage of the diversity created in vivo by the 
immune system of the donor. These types of libraries are enriched in antigen-
specific Abs, some of which have already been affinity matured by the immune 
system of the donor, and thus serve as a rich source of Abs with higher affinities 
than those obtained from other sources. In addition, large-sized immune libraries 
are not necessary in order to obtain high-affinity antibodies. Multiple immune 
libraries have been constructed and reported, including mouse (Clackson et al., 
1991; Chester et al., 1994; Kettleborough et al., 1994), human (Barbas et al., 1993), 
chicken (Yamanaka et al., 1996), rabbit (Lang et al., 1996) and camel (Arbabi 
Ghahroudi et al., 1997). The amplified V genes of an immune library are then cloned 
into a display vector for selection of binders with high affinity and specificity to the 
target antigen. Despite these advantages, immune libraries also have some 
limitations. Firstly, active immunization is not always possible due to ethical 
constraints, or is not effective due to toxicity to or tolerance mechanisms towards 
the antigen used. Secondly, immune libraries require repeated antigen immunization 
and library construction for each antigen used. Ideally, universal and antigen-
unbiased libraries should be screened to select high affinity Abs to any chosen 
antigen independent of the immune history. At present, a few such libraries have 
already been described, either naïve or synthetic (depending upon the source of the 
immunoglobulin genes), and are particularly useful for the selection of human Abs.  
 
A naïve library, if sufficiently large and diverse, can be used to generate Abs for a 
large panel of antigens, including self, non-immunogenic and relatively toxic 
antigens. The murine naïve repertoire has been estimated to contain <5x108 
different B-lymphocytes, while the human repertoire maybe a hundred to a 
thousand times bigger (Winter et al., 1994). The affinity of Abs selected from a naïve 
library is proportional to the size of the library, ranging from 10-6 to -7 M for a library 
with 107 clones (Griffiths et al., 1994), to 10-8 to -10 M for a large repertoire of about 
1010 clones (Vaughan et al., 1996). Synthetic Ab repertoires contain Abs built 
artificially by the in vitro assembly of V-gene segments and D/J segments. V-genes 
may be assembled by introducing a predetermined level of CDR randomization into 
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germline V-gene segments or re-arranged V-genes. The regions and degree of 
diversity may be chosen to correspond to areas of highest natural diversity of the 
Ab repertoire, like in the loop central to the antigen-combining site i.e. the CDR3 of 
the heavy chain. Several synthetic libraries have been constructed and been used to 
select Abs against different antigens like haptens (Barbas et al., 1992; Hoogenboom 
and Winter, 1992), proteins (Nissim et al., 1994) and cell-surface markers (de Kruif et 
al., 1995), but their affinities are typically around 10-6 to -7 M.  
2.2 Surface display methods for screening of Ab libraries 
In vitro display technology is based on the linkage of phenotype to genotype and is 
currently one of the major technologies for creating mAbs for human therapy, in 
addition to the use of transgenic mice carrying human Ig genes (Jakobovits et al., 
2007) and the humanization of mAbs (Lee et al., 2014). It involves the display and 
screening of Ab gene libraries on the surface of a biological entity e.g. 
bacteriophages, yeasts or ribosomes (Hoogenboom, 2005). Selection systems 
include the in vitro display technologies as well as protein complementation-based 
strategies. The function of a selection system is to enable isolation of specific 
affinity proteins from the majority of non-binding background proteins present in the 
library, as well as to co-select the encoding DNA in order to simplify amplification 
and identification. It is important that selection pressure is dominated by high 
affinity for the antigen, while potential biases like differences in expression levels or 
amplification rate are minimized. Many different selection methods have been 
widely used, including selection on antigen immobilized on polystyrene plates or 
columns, selection on biotinylated antigen in solution, selection on mammalian cells 
expressing a surface antigen (Cai and Garen, 1995; de Kruif et al., 1995), 
enrichment on tissue sections (Van Ewijk et al., 1997) and selection in vivo using 
living animals (Zou et al., 2004; Deramchia et al., 2012). 
2.2.1 Phage display 
In 1985, George Smith reported the use of recombinant DNA technology for display 
of heterologous peptides on the surface of filamentous phages, laying the ground 
for the “phage display” technology (Smith, 1985). This technology has proven to be 
a very powerful technique to display libraries containing billions of different peptides 
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and proteins, including Abs and is the most common Ab display method in use. 
DNA encoding Ab fragments is cloned in phagemids as a fusion to the phage coat 
proteins (e.g. pIII, pVIII). Upon expression of the Abs, the coat protein fusion is 
incorporated into new phage particles that are assembled in bacteria. Expression of 
the phage coat protein fusion product, and its subsequent incorporation into the 
mature phage coat results in the Ab or Ab fragment being presented on the phage 
surface. Bacteriophages displaying relevant Abs or Ab fragments on the surface 
(Figure 5A and 5B) are retained during selection methods, while non-adherent 
phages are washed away (Figure 5C). Bound phages are recovered by elution, 
reinfected into E. coli and re-grown for further enrichment and eventually analysis of 
binding. The most commonly used phage for display is the non-lytic filamentous 
phage, M13 and the most extensively used phage coat protein is the pIII (present in 
three to five copies per phage particle), which is involved in recognition of F-pilus 
and Tol-proteins in the bacterial cell envelope during infection (Winter et al., 1994; 
Vodnik et al., 2011). The vast majority of reports using phage display utilize scFv 
libraries (Hust and Dubel, 2004), since the smaller size and the composition from a 
single polypeptide facilitate production and folding in E. coli, thus allowing a more 
efficient presentation of the Ab repertoire on the phage surface. More complex 
proteins like Fab fragments or full-length Abs have also been expressed, but the 
necessity to produce two different polypeptide chains, has led to construction of 
bicistronic expression vectors with increased complexity (Hust and Dubel, 2005; 
Mazor et al., 2010). The major advantages of phage display include the large library 
sizes that can be attained in E. coli, i.e. 1010 members, and the high titres that can 
be produced (>1013 phage particles/ml) thus accounting for a good representation 
of all clones in the library. Secondly, purification of soluble Ab fragments is possible 
directly, after selection by phage display, without the need for re-cloning in a 
different protein expression vector. However, phage display suffers limitations such 
as high background binding due to the sticky nature of phages, the need for 
bacterial infection to produce phage-Ab particles in each round of selection, 
including titre of the phage particles produced, leading to longer experimental 
procedures, and the unfeasibility of fluorescence activated cell sorting (FACS) or 
flow cytometry for analysis due to the small size of the phage particles. 
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Figure 5. Phage display of antibodies. 
(A) Soluble Ab fragments, depicted as a scFv , are exported to the periplasm with an N-terminal 
signal peptide (e.g. PelBss). The Ab fragment can also be fused at its C-terminus to the minor coat 
protein III (pIII) of filamentous phages for phage display. In this case, the Ab fragment is exposed to 
the periplasm but tethers to the inner membrane (IM) of E. coli by pIII. (B) Phage-scFV particles 
assembled upon infection of E. coli cells expressing Ab-pIII fusions with a helper phage. The Ab-pIII 
fusion is displayed on the phage capsid (usually one copy per phage), which contains the phagemid 
DNA with the Ab gene. (C) Scheme of the steps involved during panning of phage display libraries on 
plates coated with antigen. 
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2.2.2 Cell surface display 
Cell surface display systems are effective alternative methods for Ab engineering by 
directed evolution, and show great promise in both medical and industrial 
applications. Various cell surface display systems have been developed in a range 
of host organisms, including Gram negative bacteria (Daugherty, 2007; Mazor et al., 
2007), Gram positive bacteria (Wernerus and Stahl, 2004; Fleetwood et al., 2012), 
yeast (Boder and Wittrup, 2000; Feldhaus and Siegel, 2004; Wen et al., 2011; Boder 
et al., 2012), insect cells/baculovirus (Makela and Oker-Blom, 2008) and mammalian 
cells (Ho et al., 2006; Beerli et al., 2008). These systems complement phage display 
and cell-free protein engineering systems. Currently, yeast and bacteria are the 
most commonly used cell surface display platforms for protein engineering. 
2.2.2.1 Yeast Display 
The eukaryotic secretory pathway, coupled with protein folding and quality control 
mechanisms of yeast allows a wide variety of proteins to be displayed, including 
many proteins with complex folds like single-chain T-cell receptors (scTCRs) 
(Richman et al., 2009; Aggen et al., 2011), human major histocompatibility (MHC) 
class II molecules (Wen et al., 2011), human epidermal growth factor (EGF), 
cytokines, extracellular domains of epidermal growth factor receptor (EGFR), scFvs 
(Feldhaus and Siegel, 2004) and Fabs (Blaise et al., 2004; Weaver-Feldhaus et al., 
2004; Lin et al., 2012). Proteins are displayed on the yeast Saccharomyces 
cerevisiae cell surface via fusion to the α-agglutinin yeast adhesion receptor, which 
is located in the yeast cell wall (Figure 6A). The display level on the cell is variable 
(on an average about 3x104 fusions per cell for a scFv), but the intrinsic avidity of 
this display system is counteracted by the power of cell sorting. By staining cells 
with both fluorescently labelled antigen and anti-epitope tag reagent, the yeast cells 
can be sorted according to the level of antigen binding and Ab expression on the 
surface (Figure 6B). Non-immune human scFv libraries with over 109 members have 
been generated and efficiently selected using magnetic beads (Yeung and Wittrup, 
2002; Feldhaus et al., 2003; van den Beucken et al., 2003) and then sorted by flow 
cytometry to yield Abs with nanomolar affinities (Feldhaus et al., 2003).  
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Figure 6. Yeast display of antibodies. 
(A) Ab fragments, depicted as a scFv in this scheme, are fused at its C-terminus to the Yeast 
agglutinin receptor (Aga) present on the yeast surface for display. (B) A schematic of Fluorescence 
assisted cell sorting (FACS) using yeast-displayed Ab fragments is depicted.  
Yeast display has been used with a much more diverse range of proteins than 
prokaryotic hosts. A comparative study carried out using phage and yeast display; 
with a HIV-1 immune scFv library against the HIV-1 gp120 envelope glycoprotein 
showed that although both libraries yielded the same six scFvs, yeast display 
identified an additional twelve clones. Only five of these twelve clones could be 
displayed on the phage particle, likely due to the greater protein folding capabilities 
of yeast (Bowley et al., 2007). Limiting factors of yeast display include the smaller 
library sizes due to the low transformation efficiency of yeast, longer experimental 
time due to slower culture growth and low speed of fluorescent cell sorting (FACS).  
 
A table comparing the two most common Ab display methods in use i.e phage 
display and yeast display is illustrated in Table 1.    
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Table 1. Benefits and Limitations of Phage display and Yeast Display. 
 
2.2.2.2 Bacterial cell surface display 
Although both phage display and yeast display are good Ab display systems, they 
suffer from some limitations (Table 1). Hence, it would be beneficial to develop an 
Ab display system that could combine the major advantages of both methods, while 
improving on the limitations. Bacterial display could be an alternative to these 
existing platforms of Ab display. Firstly, the larger size of bacteria than phages 
allows the use of flow cytometry based methods for selection, screening and 
characterization of clones. Secondly, bacteria are less sticky than phages, could 
result in lower background levels and selection could be carried out more easily 
using complex antigenic surfaces such as cells. Lastly, the faster growth of bacteria 
such as E. coli compared to that of yeast, greatly reduces experimental times and 
this fact combined with the highly versatile protein expression systems and 
methods available in E. coli, makes this method of Ab display very attractive. 
Escherichia coli is currently the most commonly used host for protein engineering 
by bacterial surface display, though a few reports used Gram-positive bacteria for 
display of enzymes and Ab fragments (Kronqvist et al., 2008; Fleetwood et al., 
2012). 
2.3 E. coli cell surface display of Ab libraries 
The expression of Abs in E. coli, both full-length IgGs molecules and smaller 
antigen-binding fragments, provides a set of powerful technologies for the 
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generation of Abs with novel specificities and improved properties (Holliger and 
Hudson, 2005; Beck et al., 2010). A major advantage of this display platform is that 
the relatively high transformation efficiencies of E. coli allow Ab libraries with up to 
1010 members to be constructed. Moreover, E. coli remains a suitable 
microorganism for the generation, amplification and maintenance of large Ab 
repertoires owing to its versatile protein expression and secretion systems.  
 
Although E. coli lacks eukaryotic protein folding and post-translational modification 
machineries, it allows expression of many eukaryotic proteins or protein domains in 
functional form, including the V domains of Igs. E. coli cells have an inner 
membrane (IM) and an outer membrane (OM) separated by periplasmic space. The 
presence of the OM in E. coli has hindered the development of effective cell surface 
display methods for Ab selection. In addition, display of heterologous proteins on 
the surface of E. coli often affects cell physiology, resulting in growth arrest, cell 
lysis and poor display performance. In order to be displayed on the surface, the 
polypeptides produced in the cytoplasm have to traverse the IM, the periplasm and 
be inserted into the OM. Thus, OM proteins native to the organism have served as 
convenient targeting and anchoring portions and are widely used for display, though 
heterologous anchor proteins have also been evaluated. Several E. coli surface 
display systems have been described for display of peptides, enzymes and other 
proteins (Bessette et al., 2004; Rice et al., 2006; Hall et al., 2007; Dane et al., 2009; 
Kenrick and Daugherty, 2010; Little et al., 2011; van Bloois et al., 2011), but very 
few of these are focussed on the surface display of Abs, either full length or Ab 
fragments (Figure 7). 
 
Georgiou and co-workers demonstrated in a proof-of-principle experiment that 
scFvs could be functionally displayed on the surface of E. coli and that FACS could 
be employed to isolate target-binding bacteria spiked in the background of non-
binding cells (Francisco et al., 1993), and performed the first cell sorting of a library 
of scFv mutants. Both these experiments displayed anti-digoxin scFv libraries 
containing up to 4 x 106 scFvs on E.  coli as N-terminal fusions to a chimeric 
lipoprotein (Lpp-OmpA'). Lpp-OmpA' is composed of the N-terminal signal peptide 
and the first nine residues of the mature Lpp fused to the residues 46 to 159 of 
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OmpA, which is a truncated fragment of its native 8-stranded β-barrel.  The Lpp-
OmpA´ format was the first bacterial display system to be combined with flow 
cytometry for library screening and used in protein engineering applications 
(Daugherty et al., 1998). scFv variants that bound digoxin with a KD of <1 nM were 
identified. However, Lpp-OmpA' fusions were found to be toxic to the host cells 
primarily due to membrane disruption, and resulted in lysed cultures following 
protein induction (Christmann et al., 1999; Daugherty et al., 1999). 
 
Figure 7. E. coli display of antibodies. 
(A) Lpp-OmpA´ display  (B) Anchored Periplasmic Expression (APEx) of scFvs and IgGs. 
 
Displaying proteins of interest on the periplasmic side of the IM of E. coli s also a 
valuable display system for protein engineering. Advantages of this system include 
the lack of complex carbohydrates like LPS, that could sterically interfere with 
protein binding to large targets, and that the protein of interest is required to 
traverse only one membrane, which avoids factors that may restrict export. The 
anchored periplasmic expression (APEx) system anchors the protein of interest to 
the inner membrane, either as an N-terminal fusion to a six-residue sequence 
derived from the native E. coli lipoprotein NlpA or as a C-terminal fusion to the pIII 
gene that codes for the minor coat protein of M13 (Harvey et al., 2004). A slight 
modification of the APEx system enabled the display of full-length Abs. Abs are 
secreted into the bacterial periplasm, where they are captured by an inner 
membrane protein that binds their Fc domain. After permeabilization of the outer 
membrane, the displayed antibodies could interact with fluorescently labeled 
antigen, and binding clones were selected by flow cytometry. As the anchoring 
protein is not encoded by the plasmid carrying the antibody genes, soluble, full-
length, aglycosylated IgG molecules can subsequently be produced by 
transformation of a bacterial strain devoid of the Fc-binding anchor protein (Mazor 
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et al., 2007). However, library screening involves the permeabilization of the OM (to 
permit access of the fluorescently labelled antigen to the periplasm) generating 
spheroplasts followed by sorting using FACS of these spheroplasts. Disruption of 
the OM and spheroplast production decreases dramatically the viability of bacteria 
and the isolated clones after FACS cannot be amplified by simple growth, thus 
requiring amplification of the enriched Ab genes by PCR and subcloning for the next 
round of sorting. Hence, although both the Lpp-OmpA' and APEx are good 
technologies for Ab selection, alternative methods that enable direct display of Abs 
or Ab libraries on the outer surface of E. coli cells, with little cellular toxicity and 
without the need for generation of Phabs or spheroplasts, would be of great 
interest.  
 
Integral OM proteins and secreted proteins with OM-anchoring domains have also 
been used for display of Abs on the surface of E. coli (Lofblom, 2011), of which the 
autotransporters (AT) and Intimins stand out by their apparent simplicity and 
modularity as attractive systems (Wentzel et al., 2001; Rutherford and Mourez, 
2006; Jose and Meyer, 2007; Wilhelm et al., 2011; Leo et al., 2012; Leyton et al., 
2012b; Nicolay et al., 2013; Zude et al., 2013). These proteins play important roles 
in the virulence and survival of both pathogenic and environmental Gram-negative 
bacteria. Protein members of the AT and Intimin families are a part of the type V 
secretion system of Gram-negative bacteria (Leo et al., 2012). Intimins and ATs are 
large, secreted polypeptides that contain three functional regions: i) a N-terminal 
SP, that drives their Sec-dependent translocation across the IM; ii) a β-domain, that 
is anchored into the OM by a 12-stranded β-barrel with an internal peptide linker; 
and iii) a passenger region, that is secreted to the extracellular milieu (Leyton et al., 
2012a). The passenger domains are highly diverse and carry the specific AT 
functions which maybe enzymatic, proteolytic, cytotoxic or adhesive (in the case of 
Intimin), and contribute to colonization, immune evasion and biofilm formation. 
Although, their mechanism of secretion remains uncertain, both AT and Intimin 
appear to use the β-barrel assembly machine (BAM) complex of the OM for 
insertion and translocation of the passengers to the cell surface (Figure 8) 
(Bernstein, 2007; Bodelon et al., 2009; Leyton et al., 2012a; Gruss et al., 2013; 
Noinaj et al., 2013). 
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Figure 8. Proposed mechanism of the biogenesis of protein members belonging to the type V 
secretion system (T5SS). 
Autotransporters and Intimins are members of the T5SS and their secretion to the extracellular 
medium shares a common mechanism. Secretion of Intimin is shown in the Figure. Intimin is 
translocated across the IM via the Sec-translocon. In the periplasm, DsbA catalyzes the formation of 
the disulfide bond (S-S) present in the D3 domain of Intimin. Intimin mostly follows the SurA pathway 
for its delivery to to the BAM complex, which is responsible for folding and OM insertion of its β-
barrel domain. The alternate DegP/Skp pathway is used less frequently and is depicted with a 
dashed line. The LysM domain is predicted to bind the peptidoglycan (PG) layer. Translocation of the 
secreted domains D0 (green oval), D1, D2 and D3 is believed to take place concomitantly with 
insertion of the β-domain in the OM via the BAM complex. Based on (Bodelon et al., 2009; Fairman 
et al., 2012) 
 
Despite their similarities, AT and Int/Inv proteins have important differences. They 
have opposite topological organization in the OM, the exposed passenger being 
located in the N-terminal region in AT, whereas is found at the C-terminus in the 
case of Int/Inv proteins (Figure 9). The distinct topologies are also reflected in their 
β-domains. In the case of AT, the first strand of the β-barrel is preceded by an α-
helix linker that fills the lumen and connects its N-terminus with the passenger 
region (Oomen et al., 2004; Barnard et al., 2007). In contrast, the last strand of the 
β-barrel of Int/Inv proteins is followed by a peptide linker that runs through the 
lumen in an extended conformation connecting its C-terminus to the passenger 
region (Fairman et al., 2012). In addition, the natural passenger domains of AT and 
Int/Inv have distinct structures, i.e. β-helical rods in most ATs and tandems of Ig-like 
domains in Int/Inv proteins (Luo et al., 2000; Otto et al., 2005).  
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Figure 9. Modular organization and structure of AT and Intimin proteins.  
(A) Scheme of AT proteins, showing the N-terminal SP, a secreted passenger domain, and an OM 
anchored C-terminal β-domain. Crystal structures of the passenger domain of Hbp (an AT protein 
from E. coli) (Otto et al., 2005) and β-domain of NalP (an AT protein from N. meningitidis) are shown. 
(B) Scheme of Intimin, showing the N-terminal SP, an OM anchored β-domain and a C-terminal 
passenger domain. The passenger consists of three Ig-like domains (D0, D1 and D2) and a lectin-like 
domain (D3). Crystal structures of the passenger domain (Luo et al., 2000) and the OM β-barrel 
(Fairman et al., 2012) of Intimin are shown.  
Previous studies from our laboratory showed that the AT protein, IgA protease 
(IgAP) from Neisseria gonorrhoeae could display model scFv and sdAb clones on 
the surface of E. coli fused to its β-domain (Veiga 2004). In addition, improved 
display levels of a model sdAb on E. coli cells were observed when the β-domain of 
EhaA, an AT from enterohemorrhagic E. coli (EHEC) O157:H7 was used (Marin et 
al., 2010). The displayed sdAb was correctly folded with the canonical disulfide 
bond of V domains formed by the action of DsbA (Veiga et al., 2004; Marin et al., 
2010). In a different study, the expression of Intimin from EHEC and 
enteropathogenic E. coli (EPEC) strains was demonstrated in E. coli K-12 cells with 
the display of its native Ig-like and lectin-like domains on the bacterial surface with 
a disulfide bond formed by DsbA (Bodelon et al., 2009). However, the utility of the 
β-domains of EhaA and Intimin for the display of Ab libraries had not been 
investigated. Hence, in this work we have evaluated these systems for display and 
selection of sdAbs from immune libraries raised against diverse antigens of 
biomedical importance, viz. a protein involved in the infection of enteropathogenic 
and enterohemorrhagic E. coli strains (i.e. Tir); a human serum protein that plays an 
important role in the blood coagulation (i.e. fibrinogen); and a tumor antigen 
overexpressed on the cell surface of many epithelial tumors, i.e. Epidermal growth 
factor receptor 1 (EGFR/HER1).  
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The objectives of this work were as follows: 
1) To evaluate and compare the β-domains of Intimin and EhaA proteins from EHEC 
for the display of functional sdAbs on the surface of E. coli. 
2) To utilize the E. coli display systems based on the β-domains of Intimin and EhaA 
proteins for expression of immune libraries of sdAbs and selection of high-affinity 
clones binding protein antigens of bacterial and human origin. 
3) To characterize sdAbs selected by E. coli display and determine their binding 
affinities and specificity using flow cytometry of E. coli cells, as well as compare the 
data with that obtained with standard biochemical technologies (ELISA and SPR). 
4) To apply the E. coli display platform for direct selection of sdAbs on live tumor 
cells expressing a relevant antigen such as EGFR on their surface. 
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1. Bacterial strains  
The bacterial strains used in this work are described in Table 2. 
Table 2. Bacterial strains used in this work. 
Name Genotype / Characteristics     References 
 BL21 
(DE3) 
F- ompT hsdSB(rB–, mB–) gal dcm lon λ(DE3) 
[lacI lacUV5-T7 gene1 ind1 sam7 nin5]) 
Novagen 
 
DH10B-T1R
  
 
F- mcrA Δmrr-hsdRMS-mcrBC φ80lacZDM15  
ΔlacX74 recA1 endA1 araD139 Δ(ara,leu) 
7697 galU galK rpsL (StrR) nupG tonA λ- 
 
Invitrogen 
 
MG1655 
 
K-12  (F- λ-)   
 
(Blattner, 1997) 
 
EcM1 
 
MG1655ΔfimA-H 
 
(Blomfield et al., 1991) 
 
UT5600
  
 
K-12  (F- λ-) Δ(ompT-fepC)266 
 
(Grodberg and Dunn, 
1988) 
 
WK6 
  
Δ (lac-proAB), galE, strA, nal, F’[lacIqZDM15,  
proAB] 
 
(Zell and Fritz, 1987) 
 
HB2151
  
 
K-12 Δ(lac-proAB), ara, nalR, thi, 
F’[lacIqZDM15, proAB]  
 
(Carter et al., 1985) 
 
HM140 
 
F- ΔlacX74 galE galK thi rpsL (StrA) ΔPhoA 
(PvuII) degP ptr ompT eda tsp rpoH15 
 
(Meerman and 
Georgiou, 1994) 
 
 
2. Conditions of bacterial growth 
The E. coli DH10B-T1R strain was used in the preparation of electrocompetent cells 
for use in the cloning experiments. Bacteria carrying plasmids with VHH were grown 
at 30 oC in Luria–Bertani (LB) liquid medium or on agar plates with the appropriate 
antibiotic for plasmid selection. LB plates and pre-inoculum media prior to induction 
contained 2% (w/v) glucose for repression of the lac promoter. The preinocula 
cultures were started from individual colonies (for single clones) or from a mixture of 
clones (in case of libraries), freshly grown and harvested from plates, diluted to an 
initial OD600 of 0.5, and grown overnight (o/n) under static conditions. For induction, 
bacteria (corresponding to an OD600 of 0.5) were harvested by centrifugation (4000 
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xg, 5 min), and grown in the same media with 0.05 mM isopropylthio-β-D-
galactoside (IPTG), but without glucose for 3 h with agitation (160 rpm), unless 
indicated otherwise. For over-expression of soluble VHH in the periplasm, E. coli 
WK6 cells with the corresponding pCANTAB6-VHH plasmid (Ap
R) were induced with 
0.3 mM IPTG for 3 h at 30 ºC. Secretion of VHH into the culture media was 
performed using the hemolysin (Hly) secretion system of E. coli HB2151 cells 
carrying pVDL9.3 (HlyBD; CmR) and the corresponding pEHlyA4SD-VHH (ApR) 
plasmids, induced with 0.3 mM IPTG for 6 h. Over-expression of soluble TirMEHEC 
with N-terminal His-tag was induced in E. coli BL21 (DE3) cells carrying the pET28a-
TirMEHEC plasmid (Km
R) and grown at 37 ºC in LB medium containing 1.0 mM IPTG 
for 2 h. For over-expression of soluble VHH as MBP fusions in the periplasm, E. coli 
HM140 strain with the corresponding pMAL1-VHH plasmid (Ap
R) was induced with 
0.3 mM IPTG for 3 h with agitation (250 rpm). 
3. Cell lines and Growth conditions 
Frozen aliquots of mouse fibroblast cells, viz. NIH 3T3 2.2 and HER14 were thawed 
and seeded into culture flasks (BD Falcon) containing 25 ml DMEM (Sigma) 
supplemented with 10% Fetal bovine serum (FBS, Sigma), 2 mM Glutamine, and 
grown in an incubator (Thermo Scientific) at 37º C with 5% CO2. Cells were 
subcultured periodically, when the cultures attained a confluency of ~80%. In 
experiments of selection of VHH libraries on cells, growing cells in culture were 
trypsinized and seeded in 6-well plates (Falcon) containing growth media to a 
confluency of ~20%, the day before the experiment. For Immunofluorescence 
microscopy (IFM) experiments, cells were seeded and grown on circular coverslips 
(previously irradiated with UV for 30 mins) present in 24-well plates (Falcon), prior to 
infection with bacteria, staining and analysis under the microscope. 
4. DNA constructions 
The plasmid constructions used in this work were carried out using standard 
techniques of DNA amplication and modification as described by Ausubel et al, 
1997. 
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Table 3. List of plasmids used in this work. 
Name Characteristics References 
pAK-Not (CmR), lacIq-Plac promoter, pBR322 ori (Veiga et al., 1999) 
pHEA 
pAK-Not derivative; for fusions to C-EhaA (pelB-His-E-
tag-EhaA989-1327) 
(Marin et al., 2010) 
pVgfpA 
pHEA-derivative; Vgfp fused to C-EhaA (pelB-Vgfp-E-tag-
EhaA989-1327) 
(Salema et al., 
2013) 
pVTIRnA 
pHEA-derivative; VTIR (n clone) fused to C-EhaA (pelB-
VTIRn-E-tag-EhaA989-1327) 
(Salema et al., 
2013) 
pVFIBnA 
pHEA-derivative; VFIB (n clone) fused to C-EhaA (pelB-
VFIBn-E-tag-EhaA989-1327) 
This work 
pNeae pAK-Not derivative; Neae[IntiminEHEC (1-659)-E-His-tag] 
(Bodelon et al., 
2009) 
pNeae2 
pNeae-derivative; for fusions to Neae-myc  [IntiminEHEC (1-
659)-E-His-myc tag] 
(Salema et al., 
2013) 
pNVgfp 
pNeae-myc-derivative; NVgfp fusion [IntiminEHEC (1-659)-E-
Vgfp-myc tag] 
(Salema et al., 
2013) 
pNVTIRn 
pNeae-myc-derivative; NVTIR (n clone) fusion [IntiminEHEC 
(1-659)-E-VTIRn-myc tag] 
(Salema et al., 
2013) 
pNVFIBn 
pNeae-myc-derivative; NVFIB (n clone) fusion [IntiminEHEC 
(1-659)-E-VFIBn-myc tag] 
This work 
pNVEGFRn 
pNeae-myc-derivative; NVEGFR (n clone) fusion [IntiminEHEC 
(1-659)-E-VEGFRn-myc tag] 
This work 
pCANTAB6 
(ApR), pUC-ori, for pIII fusions or soluble expression of 
sdAb with His-myc-tags 
(McCafferty et al., 
1996) 
pCANTAB6-
VTIR1 
pCANTAB6-derivative; for expression of sdAb VTIR1 with 
His-myc-tags 
(Salema et al., 
2013) 
pCANTAB6-
Vgfp 
pCANTAB6-derivative; for expression of sdAb Vgfp with 
His-myc-tags 
(Salema et al., 
2013) 
pCANTAB6-
VFIBn 
pCANTAB6-derivative; for expression of sdAb VFIB (n 
clone) with His-myc-tags 
This work 
pET28-a 
(KmR), pBR322-ori, T7 promoter; for N-terminal His-tag 
protein fusions 
Novagen 
pET28-a-
TirMEHEC 
pET28-a derivative; His-tagged TirMEHEC (residues 252 to 
360 of TirEHEC) 
(Salema et al., 
2013) 
pVDL9.3 
(CmR), pSC101-ori,  lac promoter, for production of HlyB 
and HlyD transporters 
(Fernandez et al., 
2000) 
pEHlyA2SD 
(ApR), pUC-ori, lac promoter, C-terminal E-tagged HlyA 
signal 
(Fernandez et al., 
2000) 
pEHlyA4SD 
pEHlyA2SD derivative with modified polylinker having 
unique SfiI and NotI sites 
(Salema et al., 
2013) 
pEHlyA4SD-
VTIRn 
pEHlyA4SD derivative; VTIR (n clone) fused to C-terminal 
E-tagged HlyA signal 
(Salema et al., 
2013) 
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pMAL-p2E 
(ApR), pUC-ori, contains multiple cloning sites (MCS) for 
cloning of recombinant proteins in fusion to maltose 
binding protein (MBP) and soluble expression in the 
periplasm of E. coli 
New England 
Biolabs 
pMAL1 
pMAL-p2E derivative; for sdAb fusion to MBP  [MalE-
PreScission protease site-sdAb-His tag] 
(Salema and 
Fernandez, 2013) 
pMAL1-VFIBn 
pMAL-p2E derivative, VFIB (n clone) fused to C-terminal of 
MBP, for soluble expression of sdAb, VFIB (n clone) in E. 
coli periplasm 
(Salema and 
Fernandez, 2013) 
pMAL1-Vgfp 
pMAL-p2E derivative, Vgfp fused to C-terminal of MBP, for 
soluble expression of sdAb, Vgfp in E. coli periplasm 
(Salema and 
Fernandez, 2013) 
 
Table 4. List of oligonucleotides. 
Name Nucleotide sequence (5'-3' ) 
RSP -48 AGCGGATAACAATTTCACACAGGA 
pAK-directo GTGACGCAGTAGCGGTAAACGGCAGAC 
eae4 CGTAATGGCAATAGCTCTAACAATGTA 
eae5 GACTTCAGCACTTAATGCCAGTGCGG 
VHH-Sfi2 
GTCCTCGCAACTGCGGCCCAGCCGGCCATGGCTCAGGTGCAGCTGGT
GGA 
VHH-Not2 GGACTAGTGCGGCCGCTGAGGAGACGGTGACCTGGGT 
VTIR1_CDR3_up GAGAGTAGGGATGGGCGTGTG 
VFIB1_CDR3_up GTAGTTATACTTTCCCATATCGTAC 
VFIB2_CDR3_up GGACTCGGGTGCACAGCGTCTCCA 
VEGFR1_CDR3_up CCAGTAGTCATAGTCAACGCTCCG 
VEGFR2_CDR3_up CTCAGTGGTCATGCGCGGGAAGT 
VEGFR3_CDR3_up 
CCCCAGTAGGCATATCTTTCTG 
VEGFR4_CDR3_up 
GGCCCACTTTGTAAAGATAGTATC 
VEGFR6_CDR3_up GTCATACTTCTCGGACGTTGTAG 
MalE-3'_down GCCAGCGGTCGTCAGACTGTCGATG 
pMAL-up TTGTAAAACGACGGCCAGTGCCAAGCT 
EcoRI-PreScission-SfiI CCGGAATTCCTGGAAGTTCTGTTCCAGGGGCCCGGGGCCCAGCCGGC
CATGGCTCAGGTGCAGCTGGTGGA 
HindIII-stop-myc CGGGCAGGAAGCTTTTACTATGCGGCCCCATTCAGATCCTC 
5. Protein electrophoresis and Western blot 
Whole cell protein extracts were prepared by harvesting bacteria after induction (1 
ml of OD600 1.5), resuspended in 50 µl of 10 mM Tris HCl pH 8.0, mixed with the 
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same volume of SDS-sample buffer (2X) or urea-SDS sample buffer (2X) and boiled 
for 10 min (pHEA constructs) or 30 min (pNeae constructs). The SDS-sample buffer 
(1X) consists of 60 µM Tris-HCl pH 6.8, 1% w/v SDS, 5% (v/v) glycerol, 0.005% 
(w/v) bromophenol blue and 1% (v/v) 2-mercaptoethanol (2-ME). The urea-SDS-
sample buffer (1X) contains 60 µM Tris-HCl pH 6.8, 2% w/v SDS, 4 M urea, 5 mM 
EDTA, 5% (v/v) glycerol, 0.005% (w/v) bromophenol blue and 1% (v/v) 2-
mercaptoethanol (2-ME). The boiled samples were sonicated (5 sec; Labsonic B 
Braun), centrifuged (14,000 xg, 5 min) to pellet insoluble material, loaded onto 8% 
or 10% SDS-PAGE gels and run using a Miniprotean III electrophoresis system 
(Bio-Rad). For Western blot, the gels were transferred to a polyvinylidene difluoride 
membrane (PVDF, Immobilon-P, Millipore) using a semi-dry electrophoresis transfer 
apparatus (Bio-Rad) and the membranes were blocked in phosphate buffered saline 
(PBS; 8 mM Na2HPO4, 1.5 mM KH2PO4, 3 mM KCl, 137 mM NaCl, pH 7.0) with 3% 
(w/v) skimmed milk (Milk-PBS) for 1 hour at RT. For immunodetection of the E-
tagged proteins, membranes were incubated for 1 h at room temperature (RT) in the 
same buffer with anti-E-tag mAb (Phadia), while for immunodetection of the myc-
tagged proteins anti-c-myc-POD mAb (clone 9E10; Roche) was used. Membranes 
were washed three times with PBS containing 0.1% Tween 20 to remove unbound 
Abs. Bound anti-E-tag mAb was developed using anti-mouse IgG conjugated with 
peroxidase (POD) (Sigma). Streptavidin-POD conjugate (Roche) was employed to 
detect the biotinylated broad range SDS-PAGE protein markers (Bio-Rad). All mAbs 
and POD conjugates were used in a 1:5000 dilution. For developing, a 
chemiluminescence reaction was prepared using a mixture of 1.25 mM luminol 
(Sigma) and 200 µM p-coumaric acid (Sigma) in 10 ml of 100 mM Tris–HCl (pH 8.0). 
Following a rapid rinse in PBS, the membranes were soaked in the 
chemiluminiscence mixture and H2O2 (Sigma) was added at 0.02% (v/v), followed by 
one minute incubation in the dark and the PVDF-membranes were either exposed to 
an X-ray film (Curix, Agfa) or scanned in a Chemi-Doc XRS (Bio-Rad).  To quantify 
the total number of VHH fusions expressed in E. coli, Western blots of whole cell 
protein extracts and dilutions of a purified E-tagged VHH of known concentration 
(hereafter referred to as “unknowns” and “standard”, respectively) were visualized 
on a ChemiDoc XRS and analyzed using the Quantity One software (Bio-Rad). The 
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intensity of bands from standard and unknown samples was measured and the 
local background was corrected. The total number of molecules in the various 
dilutions of the standard protein was calculated and was plotted against the 
corresponding values of density of its band (Intensity/mm2) to generate a standard 
curve. Based upon the standard curve plot, the number of molecules of VHH fusions 
in the unknown samples was estimated, assuming that ~1.5x108 bacteria (0.15 units 
of OD600) were loaded per lane. Two independent experiments were done with each 
sample in duplicates. 
6. Protease accessibility assays 
Induced bacteria (1 ml, OD600=1.5) were harvested by centrifugation (4000 xg, 3 min) 
and resuspended in 100 ml of 10 mM Tris HCl pH 8.0. This bacterial suspension 
was incubated with trypsin (10 mg/ml; Sigma) or with proteinase K (ProtK; 40 
mg/ml; Roche) as indicated, for 20 min at 37 oC. Next, the trypsin inhibitor (5 mg/ml; 
Sigma) or the serine proteases inhibitor (PMSF 1 mM; Sigma) was added to stop 
further proteolysis. The cell suspension was centrifuged (14,000 xg, 1 min), the cell 
pellet resuspended in 50 ml of 10 mM Tris HCl pH 8.0, lysed with one volume of 
SDS-sample buffer (2X) or urea-SDS-sample buffer (2X), boiled and analyzed by 
Western blot. 
7. ELISA 
TirMEHEC or BSA (Sigma) proteins were adsorbed at 4ºC o/n onto 96-well 
immunoplates (Maxisorb; Nunc) at a concentration of 5 μg/ml in PBS. Next, 
immunoplates were washed in PBS and blocked by incubation with 200 μl of 3% 
(w/v) Milk -PBS for 2 h at RT. The sdAbs (secreted or purified) were diluted in 3% 
(w/v) Milk-PBS, added at the indicated concentrations (0.1-100 nM) in duplicates 
and incubated for 1 h at RT. After incubation, the wells were washed three times 
with PBS (Immunowash 1575, Bio-Rad) and the bound sdAbs was detected by the 
addition of anti-c-myc-POD mAb (clone 9E10; Roche; 1:1000), or anti-E-tag mAb 
(Phadia; 1:1000) followed by anti-mouse-POD (Sigma; 1:1000) for E-tagged sdAb, 
and incubation of the plates for 1 h at RT. The plates were washed three times with 
PBS and developed with H2O2 and o-phenylenediamine (OPD; Sigma) as previously 
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described (Jurado et al., 2002).  The plates were read at 490 nm using the iMark 
ELISA plate reader (Bio-Rad). 
8. Purification of TirMEHEC 
500 ml cultures of induced E. coli BL21(DE3) cells carrying pET28a-TirMEHEC, were 
centrifuged (4000 xg, 15 min, 4ºC) and the pellet was resuspended in 25 ml of PN3 
buffer (50 mM sodium phosphate pH 7.4, 300 mM NaCl) containing DNase (0.1 
mg/ml; Roche) and a cocktail of protease inhibitors (Complete EDTA-free; Roche). 
The cells were lysed in a French Press at 1200 psi (3 cycles) and the whole cell 
lysate was ultracentrifuged (40000 xg, 1 h, 4ºC). The supernatant was loaded (flow 
rate of 1 ml/min) onto a column packed with 3 ml of a Cobalt-containing resin 
(Talon, Clontech) pre-equilibrated with 30 ml PN3 buffer. The column was 
subsequently washed with 10 ml of PN3 buffer, followed by a wash with 10 ml of 
PN3 buffer containing 5 mM imidazole and the protein was finally eluted in 1 ml 
fractions with the PN3 buffer containing 150 mM imidazole. The eluted fractions 
were dialyzed against HEPES-buffer (20 mM HEPES pH 7.4, 200 mM NaCl, sterile 
filtered and degassed).  Dialyzed fractions were concentrated 10 fold in a 3-kDa 
centrifugal filter unit (Amicon Ultra-15) and loaded onto a gel filtration column 
(HiLoad 16/600 Superdex 75 preparative grade, GE Healthcare), pre-equilibrated 
with HEPES-buffer and calibrated with protein markers (Gel Filtration Standards, 
Bio-Rad) and Blue dextran (for exclusion volume V0; Sigma). Fractions of 1 ml 
containing TirMEHEC were collected and checked for purity by SDS-PAGE. Protein 
concentration was estimated using the Bicinchoninic acid (BCA) Pierce protein 
assay kit (Thermo Scientific). 
9. Magnetic Cell Sorting (MACS) of VHH immune libraries 
Induced E. coli cells (equivalent to a final OD600 of 5.0) were harvested by 
centrifugation (4000 xg, 3 min), washed three times with 2 ml PBS (sterile filtered 
and degassed), and resuspended in a final volume of 1 ml of PBS. Biotinylated 
antigen (TirMEHEC , hFib or rhEGFR, at concentrations indicated) was added to 100 µl 
of bacteria, the final volume was adjusted to 200 µl with PBS-BSA (PBS 
supplemented with 0.5% w/v BSA, sterile filtered and degassed), and incubation 
was carried out for 1 h at RT. After incubation, bacteria were washed three times 
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with 1 ml of PBS-BSA, resuspended in 100 ml of the same buffer containing 20 µl of 
anti-biotin paramagnetic beads (Miltenyi Biotec) and incubated at 4 ºC for 20 min. 
Next, bacteria were washed three times with 1 ml of PBS-BSA, resuspended in 500 
µl of the same buffer, of which 10 µl was kept aside to calculate the input bacteria 
before the procedure, while the rest (490 µl) was applied onto a MACS MS column 
(Miltenyi Biotec), previously equilibrated with 500 µl of PBS-BSA and placed on the 
OctoMACS Separator (Miltenyi Biotec). The flow through of unbound cells was 
collected and the column was washed three times with 500 µl of PBS-BSA. The 
wash was combined with the flow-through as “Unbound fraction”. Next, the column 
was removed from the OctoMACS Separator and placed onto a new collection 
tube, 2 ml of LB was added and the cells were eluted out. This fraction was labeled 
as the “Bound fraction”. Serial dilutions of Unbound and Bound fractions were 
plated to determine CFU and to harvest the bound bacteria. 
10.  Flow cytometry of VHH clones or VHH immune libraries 
For standard flow cytometry, induced bacterial cells (equivalent to a final OD600 of 
1.0; ~109 CFU) were harvested by centrifugation (4,000 xg, 3 min), washed twice 
with 500 µl of PBS (filter-sterilized) and resuspended in a final volume of 400 µl of 
PBS. Next, 190 µl of this cell suspension (~3x108 CFU) was incubated with the 
primary Ab or antigen (as indicated) and PBS was added to adjust the total volume 
to 200 µl. The primary Abs (for assay of expression levels) were anti-E-tag mAb 
(1:200; Phadia) or anti-c-myc mAb (1:200; 9B11 clone; Cell Signalling), while 
biotinylated antigens (GFP, TirMEHEC, hFib, rhEGFR or BSA) were used at 50 nM for 
assay of antigen binding, unless otherwise indicated. The samples were incubated 
at RT for 1h. After incubation, the cells were washed once with 500 µl of PBS, and 
resuspended either in 500 µl of PBS containing 1 µl of anti-mouse-IgG1 conjugated 
to Alexa 488 Fluor (2 mg/ml, Invitrogen) or in 200 ml of PBS containing 30 µl of 
1:200 dilution of Streptavidin-phycoerythrin (PE) (0.5 mg/ml, Beckman Coulter). The 
mixture was incubated 30 min at 4 ºC in the dark. The cells were washed once with 
500 µl of PBS and resuspended in a final volume of 1 ml in PBS. For each 
experiment at least 100,000 cells were analyzed in a cytometer (Gallios, Beckman 
Coulter). 
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11.  Affinity Determination by Flow cytometry 
Induced E. coli cells (equivalent to final OD600 of 1) were centrifuged (4000 xg, 3 
min), washed twice with 1 ml of PBS (filter-sterilized) and resuspended in a final 
volume of 1 ml of PBS. Next, 50 µl of this cell suspension (~3x107 CFU) was 
incubated at room temperature for 90 min with a fixed amount of biotinylated 
TirMEHEC  and hFib (2 pmols) or rhEGFR (1 pmol) and increasing volumes of PBS 
(from 0.1 to 1.5 ml) to attain a final concentration range between 20 nM to 1 nM or 
100 nM to 0.8 nM respectively.  After incubation, cells were centrifuged (4000 xg, 3 
min), washed twice with 1 ml of PBS (filter-sterilized) and labeled with Streptavidin-
PE as described for standard flow cytometry. After a final washing step with PBS, 
the mean fluorescence intensity (MFI) of Phycoerythrin (PE) was quantified in a 
cytometer (Gallios, Beckman Coulter). Data of MFI (relative values to maximum MFI) 
obtained from the cytometer were plotted against the concentration of biotinylated 
antigen to obtain the dissociation constant (KD). Curve was fitted according to non-
linear least squares regression method and one site - specific binding saturation 
kinetics model using the data analysis tool in Prism software (GraphPad). 
12.  Purification of VHHs from the periplasm of E. coli 
Soluble VHHs with His6 and myc tags in their C-termini were induced in E. coli WK6 
cells carrying pCANTAB6-VTIR1 or pCANTAB6-Vgfp. Cells were pelleted by 
centrifugation (4000 xg, 12 min, 4ºC) from 1 L cultures, resuspended in 22.5 ml 
Periplasmic Extraction buffer [50 mM Sodium phosphate pH 7.4, 200 mM NaCl, 5 
mM EDTA and 1 mg/ml polymyxin B sulphate (Sigma)] and stirred at 4ºC for 2 h 
using a magnetic stirrer. The periplasmic extract was obtained by ultracentrifugation 
(40000 xg, 30 min, 4ºC) and dialyzed o/n at 4ºC against 5 L of PN2 buffer (50 mM 
sodium phosphate pH 7.4, 200 mM NaCl). Dialyzed extract was loaded onto a 
Cobalt-containing affinity resin (Talon, Clontech), washed, and bound protein eluted 
in PN2 with 150 mM imidazole. Eluted sdAb was dialyzed, concentrated, and 
loaded onto a calibrated gel filtration column (HiLoad 16/600 Superdex 75 
preparative grade, GE Healthcare) as described previously for TirMEHEC. The 
fractions corresponding to the monomeric sdAb were collected and concentrated in 
a 3-kDa centrifugal filter unit (Amicon Ultra-15).  Protein concentration was 
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estimated using the Bicinchoninic acid (BCA) Pierce protein assay kit (Thermo 
Scientific). 
13.  Purification of VHHs from the periplasm as fusions with Maltose binding 
protein (MBP) 
Frozen pellets of E. coli cells (ca. 3 grams of wet weight), harvested from induced 1 
L cultures, were thawed in 25 ml of buffer NaPi (50 mM sodium phosphate pH 7.4, 
200 mM NaCl) containing DNaseI (0.1 mg/ml, Roche) and a cocktail of protease 
inhibitors (Complete EDTA-free, Roche). Bacteria were lysed using the French Press 
at 1200 psi (3 cycles). All of the following steps were carried out at 4ºC. The cell 
lysate was clarified by a low-speed centrifugation (5000 xg, 15 min), to pellet non-
lysed bacteria and cell debris, followed by a high-speed centrifugation (20000 xg, 
60 min) using the supernatant obtained from the previous step. The final 
supernatant was filtered through a 0.22 µm syringe filter (PVDF, Durapore, Merck 
Millipore) and loaded (at a flow rate of 1 ml/min) onto a chromatography column 
packed with 2 ml of amylose resin (New England Biolabs) pre-equilibrated with 20 
ml (10 column volumes) of buffer NaPi. All steps were performed in a BioLogic LP 
chormatography system (Bio-Rad). The column was washed with 20 ml of buffer 
NaPi, followed by elution of the MBP-fusion protein with 20 ml of buffer NaPi 
containing 10 mM D-maltose (Sigma), in 1-ml fractions. The collected fractions were 
analyzed for purity by SDS-PAGE and total protein content by the Bicinchoninic 
assay (BCA, Piercenet) with BSA as protein standard. Selected fractions of high 
protein content and purity were pooled together and dialyzed o/n against 5 L of 
buffer NaPi. Dialyzed protein samples were loaded at a flow rate of 1 ml/min onto a 
chromatography column packed with 2 ml IMAC resin (Talon, Clontech), pre-
equilibrated with 20 ml of buffer NaPi. The column was washed with 10 ml of buffer 
NaPi followed by 10 ml of buffer NaPi containing 10 mM imidazole (Sigma). MBP-
fusions were eluted with 20 ml of buffer NaPi containing 150 mM imidazole in 1-ml 
fractions. The eluted protein fractions were analyzed for protein content by BCA 
assay and purity by SDS-PAGE analysis. Selected fractions of high purity and 
protein content were concentrated 10-fold and the buffer was exchanged to NaPi in 
a 3-kDa centrifugal filter unit (Amicon Ultra-15, Merck Millipore) to remove 
imidazole.  
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In cases when VHH free from the MBP was desired, enzymatic cleavage of the MBP- 
VHHHis6 fusions was carried out using dialyzed protein samples (from above). Fifty 
units of PreScission protease® (GE Healthcare) were added to 5 mg samples of 
MBP- VHHHis6 fusions in buffer NaPi and incubated at 4 ºC for 16 h on a rolling 
wheel. Digested samples were loaded onto a chromatography column packed with 
2 ml amylose resin (New England Biolabs) in order to remove free MBP and 
undigested MBP- VHHHis6 fusions. The VHHs with C-terminal His6- and myc- tags 
were collected in the flow-through fraction and loaded directly onto a 
chromatography column packed with 2 ml IMAC resin (Talon, Clontech), as 
described above with MBP-fusions. The column was washed and VHHs were eluted 
as previously described with MBP-fusions. All steps were performed in a BioLogic 
LP chormatography system (Bio-Rad) at 4 oC.  The eluted protein fractions were 
analyzed for protein content by BCA assay and purity by SDS-PAGE analysis. 
Selected fractions of high purity and protein content were concentrated 10-fold and 
the buffer was exchanged to 20 mM HEPES pH 7.4, 200 mM NaCl in a 3-kDa 
centrifugal filter unit (Amicon Ultra-15, Merck Millipore). The concentrated protein 
was loaded at a flow rate of 1 ml/min onto a Gel-filtration column (HiLoad 16/600 
Superdex 75 pg, GE Healthcare Life Sciences) pre-equilibrated with 360 ml of 20 
mM HEPES pH 7.4, 200 mM NaCl and pre-calibrated with Gel-filtration protein 
standards (Bio-Rad) and Blue Dextran (Sigma). The fractions corresponding to the 
size of monomeric VHHs were collected, concentrated 10-fold in a 3-kDa centrifugal 
filter unit (Amicon Ultra-15, Merck Millipore) and analyzed for purity by Western blot 
and SDS-PAGE. Total protein concentration was determined by the microBCA 
protein assay (Piercenet) with BSA as the protein standard. 
14.  Surface plasmon resonance (SPR) 
SPR measurements were performed using a Biacore 3000 instrument (GE 
Healthcare).  All proteins solutions were dialyzed against HEPES-buffer [20 mM 
HEPES 200 mM NaCl (pH 7.4) sterile filtered and degassed] at 4ºC o/n. Biotinylated 
TirMEHEC (0.1 µg/ml) or Human fibrinogen (60 µg/ml) was immobilized on a 
Streptavidin SA chip (GE Healthcare) at 150 response units (RU) or 18000 response 
units (RU) at a flow rate of  10 µl/min in HEPES-buffer containing 0.005% (v/v) of the 
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surfactant Polysorbate 20 (P20, GE Healthcare). For determination of binding 
kinetics, dilutions of purified sdAb (analyte) from 32 nM to 200 pM (in case of VTIR1), 
from 40 nM to 2.5 nM (in case of VFIB1) or from 80 nM to 5 nM (in case of VFIB2) were 
flown at 30 µl/min in HEPES-buffer and sensograms were generated. The 
biotinylated antigen surface on the Streptavidin SA chip was regenerated after every 
cycle using three injections (10 µl) of 10 mM Glycine-HCl (pH 1.7) or 10 mM 
Glycine-HCl (pH 2.5) in case of TirMEHEC and Human fibrinogen respectively. 
Sensograms with the different concentrations of analyte were overlaid, aligned and 
analyzed with BIAevaluation 4.1 software (GE Healthcare). All data were processed 
using a double-referencing method. 
15.  Selection of VHH immune libraries on cells 
Mouse fibroblast cell lines i.e. NIH-3T3 2.2 (EGFR-)and HER14 (EGFR+), growing in 
monolayers in 6-well culture plates (BD Falcon) containing culture media and at a 
confluency of ∼40-50%  i.e. ∼6X105 cells were washed with Hank´s balanced salt 
solution (HBS, Sigma) solution. Induced E. coli cells (equivalent to a final OD600 of 1) 
were harvested by centrifugation (4000 xg, 3 min), washed with 2 ml HBS. 300 µl of 
washed bacteria (containing ∼6X107 cells) were added to wells with NIH-3T3 2.2 
cells and incubation was carried out for 1 h at 37ºC. After incubation, the unbound 
bacteria were recovered, added to wells containing HER14 cells and further 
incubation was carried out for 15 min at 37ºC. Next, HER14 cells were washed 
three times with 1 ml of HBS, to remove any non-specific binders and lysed by 
addition of HBS supplemented with 0.2% SDS and 0.1% DNAse. Serial dilutions of 
the cell lysate containing bacteria were plated to determine the CFU of bacteria 
recovered after the procedure. All experiments were carried out in duplicates. 
16.  Immunofluorescence microscopy (IFM) 
∼5X104 cells of the mouse fibroblast cell lines viz. NIH-3T3 2.2 and HER14 (in 
DMEM supplemented with FBS and Glutamine), were seeded onto circular 
coverslips (previously UV irradiated for 30 mins, placed in 24 well tissue culture 
treated plates), and grown in an incubator at 37º C and 5% CO2 for 36 hours. 
Induced E. coli cells (1 OD600) were washed in HBSS and used to infect the cells at a 
Multiplicity of Infection (MOI) of 100:1 for 20 mins at 37ºC. The coverslips were 
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washed by immersion in a beaker containing PBS (1X). Washed cells were fixed 
with 4% paraformaldehyde (PFA, Sigma) for 20 mins and subsequently washed ten 
times in PBS to remove excess of PFA. The coverslips were incubated at room 
temperature with the primary Ab for 45 mins (as described below), washed ten 
times in PBS and incubated with the secondary Ab (as described below) for 30 
mins. Upon incubation, the coverslips were washed ten times in PBS, mounted on 
slides using ProLong Gold anti-fade reagent (Life technologies, Ref: P36930) and 
visualized using a Zeiss Axioimager immunofluorescence microscope. 
 
Different primary and secondary Abs, diluted in PBS and 10% goat serum, were 
used to stain the eukaryotic cell and the bacteria respectively. EGFR present on the 
surface of eukaryotic cells was stained with an anti-EGFR mAb (EMD Millipore, Ref: 
GR01, dilution 1:750), while E. coli cells were stained with a rabbit anti- E. coli all 
antigens polyclonal Ab (Amsbio, Ref: B65001R, dilution 1:1500). In case of 
secondary Abs used, a rabbit anti-mouse mAb conjugated to the fluorophore Alexa 
488 (Life technologies, Ref: A-11059, dilution 1:500) stained the EGFR in green, a 
goat anti-rabbit Ab conjugated to the fluorophore Alexa 594 (Life technologies, Ref: 
A-11012, dilution 1:500) stained the bacteria in red and DAPI (4',6-diamidino-2-
phenilindole, Life technologies, Ref: D3571) stained the DNA in the microscopy 
preparations in blue.  
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Chapter 1: Display of single domain Ab clones and immune libraries 
against TirMEHEC and Human fibrinogen on the surface of E. coli 
cells 
1.1 Comparison of EhaA and Intimin β-domains for display of sdAbs on E. 
coli 
To compare the potential of Intimin and EhaA β-domains for the display of sdAbs 
we employed camelid VHH (nanobodies) (Muyldermans et al., 2009). Initial assays 
were conducted using a model VHH clone binding GFP (Vgfp) (Rothbauer et al., 
2008) fused to the β-domains of EhaA and Intimin for comparison of the two 
systems before cloning of an immune library of sdAbs. Vgfp was cloned in pHEA 
vector (Table 2) in frame with the N-terminal SP of PelB (Keen and Tamaki, 1986) 
and the C-terminal fragment of EhaA (residues 989-1327; named as C-EhaA), 
bearing its native β-barrel with α-helix linker, and including the E-tag epitope 
between the VHH and C-EhaA (Figure 10A) (Marin et al., 2010). The Vgfp sequence 
was cloned in pNeae2 (Table 2) in frame with the N-terminal fragment of Intimin 
(residues 1-659; named as Neae), comprising its N-terminal SP, periplasmic LysM 
domain (expected to bind the peptidoglycan), native β-barrel with C-terminal linker, 
the first Ig-like domain (D0); and in addition, the E-tag and myc-tag (EQKLISEEDL) 
epitopes flanking the VHH for detection of expression and binding (Figure 10B). Both 
E. coli display vectors contain unique SfiI and NotI restriction sites flanking the VHH 
in the same frame as those of conventional phagemids (e.g. pHEN6, pCANTAB6) 
(McCafferty et al., 1994). The resulting fusion proteins were referred to as VHHA 
(fusions to C-EhaA) and NVHH (fusions to Neae). 
 
The expression of VgfpA and NVgfp fusions in E. coli K-12 cells (strain UT5600; 
Table 1) was analyzed by Western blot after induction with 0.05 mM IPTG at 30 oC 
for 3 h (see Materials and Methods). Discrete protein bands corresponding to VgfpA 
and NVgfp were detected with anti-E or anti-myc mAbs in whole cell protein 
extracts from the induced cells (Figure 10C and Figure 10D). Both fusion proteins, 
i.e. VgfpA and NVgfp, showed a shift in their electrophoretic mobility (Figure 10C 
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and Figure 10D), a characteristic of native OMPs with correctly folded β-barrels, 
which makes them resistant to SDS denaturation at low temperatures and hence 
migrate faster than the unfolded polypeptides due to the compact structure of the 
β-barrel (Schnaitman, 1973; Koebnik et al., 2000).  
 
Interestingly, NVgfp was resistant to 2% SDS and 4 M urea at low temperatures (i.e. 
22 oC) and required boiling in this buffer to unfold, as previously reported for full-
length Intimin and its β-domain (Bodelon et al., 2009). The major protein bands 
detected with anti-E mAb in the boiled samples corresponded to full-length VgfpA 
and NVgfp fusions (Figure 10C and 10D; labelled with arrows). Detection of NVgfp 
with anti-myc mAb confirmed the integrity of its C-terminal end (Figure 10D). Minor 
bands of lower MW were also detected in Western blot with anti-E mAb, which 
likely represent proteolytic fragments of the full-length fusions (Figure 10C and 10D; 
labelled with asterisks).  
 
The accessibility of VgfpA and NVgfp fusions to the external milieu was initially 
compared by incubation of intact E. coli cells with externally added proteases. 
Trypsin digested full-length VgfpA leaving some weakly detectable proteolytic 
fragments with a size similar to C-EhaA and Vgfp domains (Figure 10C, lane 3). The 
NVgfp fusion was resistant to Trypsin (data not shown) and sensitive to Proteinase 
K (ProtK) (Figure 10D, lane 3) but ProtK digestion of NVgfp fusion left a resistant 
fragment comprising Neae. 
 
The induced E. coli cultures expressing VgfpA or NVgfp fusions showed only a 
slight decrease in their growth rate compared to control cultures having the empty 
vector (pAK-Not), or expressing the β-domains C-EhaA (pHEA) or Neae (pNeae2), 
and reached final optical densities at 600 nm (OD600) identical to controls (Figure 
11A and 11B). Hence, both the β-domains display the sdAb to the extracellular 
milieu, in a way that is accessible to externally added proteases but C-EhaA fusions 
are more sensitive to digestion than the Neae fusions. Resistance to proteolysis was 
also previously observed for full-length Intimin (Bodelon et al., 2009). 
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Figure 10. E. coli cell surface display of VHHs with EhaA and Intimin beta domains.  
(A) Scheme of EhaA autotransporter and VHHA fusions (left), showing N-terminal SP, secreted 
passenger or VHH domain, and C-terminal β-domain. Model of VHHA fusion in the OM (right), with N-
terminal VHH domain exposed to the extracellular milieu and with C-EhaA β-barrel inserted in the 
OM. These domains are connected with the E-tag epitope and the internal α-helical linker of the β-
barrel. (B) Scheme of Intimin and NVHH fusions (left), showing N-terminal SP, LysM and β-domains, 
and secreted D0-D3 Ig-like and lectin-like domains, or VHH domain replacing D1-D3 in NVHH fusions. 
Model of NVHH fusion in the OM (right), with N-terminal LysM domain in the periplasm, β-barrel with 
linker in the OM, and connecting with C-terminal D0 and VHH domains exposed to the extracellular 
milieu. The E-tag and myc-tag epitopes flanking the VHH domain are indicated. (C) and (D) Western 
blots of whole-cell protein extracts from induced E. coli UT5600 harbouring pVgfpA (C) or pNVgfp 
(D). Intact E. coli cells were incubated with (+) or without (-) the indicated protease, Trypsin or 
Proteinase-K (ProtK), before lysis. Protein extracts were prepared in SDS (C) or SDS-urea (D) sample 
buffers and boiled (+) or not boiled (-) before SDS-PAGE. Western blots were developed with anti-E 
or anti-myc mAb, as indicated. The positions of full-length VgfpA and NVgfp fusions are labeled with 
arrows. Asterisks indicate protein bands detected in protease-treated samples. The mass of protein 
markers (in kDa) is shown on the left. 
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Figure 11. Growth of E. coli cultures expressing VgfpA and NVgfp fusions. 
A) Growth curve of LB cultures of E. coli UT5600 cells carrying plasmids pVgfpA, pHEA (expressing 
C-EhaA), or pAK-Not (empty vector). (B) Growth curve of LB cultures of E. coli UT5600 cells carrying 
plasmids pNVgfp, pNeae2 (expressing Neae), or pAK-Not (empty vector). The cultures were 
incubated at 30 oC with agitation (160 rpm) and induced with 0.05 mM IPTG at the time indicated by 
an arrow. The optical density at 600 nm (OD600) of the cultures was monitored at the time points 
shown. 
 
 
Surface display of VgfpA and NVgfp was assessed by flow cytometry (Figure 12). 
Induced E. coli cells harboring pVgfpA, pNVgfp, or pAK-Not (control) were stained 
with anti-E or anti-myc mAbs followed by anti-mouse IgG-Alexa488 (Figure 12, left 
panels). E. coli cells expressing VgfpA or NVgfp were positively bound by anti-E 
mAb, though cells expressing NVgfp were also positively bound with the anti-myc 
mAb. Control E. coli cells with pAK-Not were negative for both mAbs. Importantly, 
the presence of a single peak in the flow cytometry histograms indicated that most 
E. coli cells were expressing a homogenous level of the fusion proteins. The mean 
fluorescence intensity (MFI) of cells with anti-E-tag mAb suggested a higher 
expression and display level of NVgfp than VgfpA (~3-fold). The antigen-binding 
activity of the surface displayed Vgfp was compared by flow cytometry after 
incubation of E. coli cells expressing these fusions with 50 nM biotin-labeled GFP 
(positive antigen) or biotin-labeled BSA (negative antigen), followed by incubation 
with Streptavidin-Phycoerythrin (PE) conjugate (Streptavidin-PE) (Figure 12, right 
panels). This analysis showed the specific binding of the E. coli cells expressing 
VgfpA and NVgfp fusions to GFP, whereas control E. coli cells did not bind GFP. No 
significant binding to BSA was observed. Hence, the β-domains of EhaA and Intimin 
allow the functional display of sdAb on the surface of E. coli cells. However, the MFI 
of GFP binding was clearly higher in E. coli cells expressing NVgfp than in those 
with VgfpA (ca. 8-fold) (Figure 12, right panels). The higher expression level of NVgfp 
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does not appear to be sufficient to account for this difference in binding, suggesting 
that the sdAb may have a higher antigen-binding activity when fused to the β-
domain of Intimin. 
 
Figure 12. E. coli cell surface display and antigen-binding activity of VgfpA and NVgfp. 
Fluorescent flow cytometry analysis of induced E. coli UT5600 cells bearing the indicated plasmids: 
pAK-Not (control), pVgfpA, and pNVgfp. Histograms show the fluorescence intensity of bacteria 
stained with anti-E or anti-myc mAbs (as indicated) and secondary anti-mouse IgG-Alexa 488 (left 
panels) or incubated with biotinylated antigens (GFP or BSA, as labeled) and secondary Streptavidin-
phycoerythrin (PE) (right panels). 
 
1.2 Construction of immune libraries against TirMEHEC and Fib, analysis of 
expression, display levels and cellular toxicity 
Two distinct immune libraries of VHH genes from dromedaries immunized with 
purified antigens were used to demonstrate the effectiveness of E. coli Intimin and 
EhaA display systems with large sdAb repertoires. An immune library of VHH was 
generated against the soluble extracellular fragment of the translocated intimin 
receptor (tir) from EHEC (named TirMEHEC, corresponding to residues 252-360 of 
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full-length TirEHEC) (Frankel and Phillips, 2008) was cloned in vectors pHEA and 
pNeae2. Similarly, another immune library against Human Fibrinogen (Fib) was also 
cloned in vectors pHEA and pNeae2. Both VHH libraries were obtained by 
immunization of a dromedary with purified antigens, i.e. TirMEHEC-His6 and Fib, and 
subsequent amplification of the VHH gene segments from ~2x107 lymphocytes 
isolated from a peripheral blood sample (see Materials and Methods).  The amplified 
VHH gene segments were cloned into the SfiI and NotI sites of pHEA and pNeae2 
vectors, generating two E. coli display immune libraries of similar size (~2-3x106 
clones). The E. coli strain EcM1 (Table 2) was used as host for cell display. This 
strain is derived from the reference wild type K-12 strain (MG1655) with a deletion in 
the operon encoding type 1 fimbriae (ΔfimA-H) (Munera et al., 2008). Sequencing of 
40 clones picked randomly from each of the two libraries in both display systems 
confirmed the cloning of different VHH sequences in frame with the β-domains of 
EhaA and Intimin respectively (data not shown). The expression and display of both 
libraries with the β-domains of EhaA (VHHA) and Intimin (NVHH) were analyzed by 
flow cytometry with anti-E and anti-myc mAbs, revealing a fairly homogeneous 
expression of both libraries in E. coli EcM1 (Figure 13A and 13C).  
 
The MFI with anti-E mAb indicated a similar expression level of VHHA and NVHH 
libraries, in contrast to the significantly lower expression of VgfpA observed 
previously. Western blot analysis of whole-cell protein extracts from induced 
cultures revealed major protein bands with the expected size for full-length VHHA 
and NVHH fusions, upon boiling in SDS or SDS-urea buffer, respectively, and which 
have heat-modifiable electrophoretic mobility indicating the correct folding of their 
β-barrels (Figure 13B and 13D). 
 
Quantification of the Western blot signals with anti-E mAb using ~1.5x108 bacteria 
(0.15 units of OD600) expressing VHHA or NVHHfusions, was carried out using a 
standard curve generated with a purified E-tagged VHH of known concentration 
(Figure 14), and allowed an estimation of ~6.5x103 molecules of VHHA and ~7.8x103 
molecules of NVHH per bacterium.  
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Figure 13. E. coli cell surface display of anti-TirMEHEC and anti-Fib immune libraries. 
Fluorescent flow cytometry analysis of induced E. coli EcM1 cells expressing either (A) VHHA or 
NVHH immune libraries anti-TirMEHEC (as indicated) or (C) VHHA or NVHH immune libraries anti-Fib (as 
indicated). Control cells carried the empty vector pAK-Not. Histograms show the fluorescence 
intensity of bacteria stained with anti-E or anti-myc mAbs (as labeled) and secondary anti-mouse 
IgG-Alexa 488. Western blots of whole-cell protein extracts from induced E. coli EcM1 cells 
expressing either (B) VHHA or NVHH immune libraries anti-TirMEHEC (as indicated) or (D) VHHA or NVHH 
immune libraries anti-Fib (as indicated). Protein extracts were prepared in SDS (VHHA library) or SDS-
urea (NVHH library) sample buffers and boiled (+) or not boiled (-) before SDS-PAGE. Western blots 
were developed with anti-E mAb. Positions of full-length fusions are labeled with arrows and mass of 
protein markers (in kDa) is shown on the left. 
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Figure 14. Quantification of the number of molecules of VHHA and NVHH fusions expressed in 
E. coli. 
The plot shows the intensity of protein bands from Western blots developed with anti-E-tag mAb and 
quantified on a ChemiDoc XRS using the Quantity One software (Bio-Rad).  Samples analyzed were 
whole-cell protein extracts from ~1.5x108 bacteria (0.15 units of OD600) of induced E. coli EcM1 cells 
carrying the pVHHA or pNVHH anti-TirMEHEC libraries. The standard curve was generated with the 
values of band intensities (Intensity/mm2) of a purified E-tagged VHH of known concentration. Two 
independent experiments were done with similar results.  
 
 
The growth of E. coli cultures expressing VHHA or NVHH libraries against TirMEHEC 
was only slightly delayed compared to a control with pAK-Not and the cultures 
reached similar OD600 after induction (Figure 15).  
 
 
 
Figure 15. Growth of E. coli cultures expressing VHHA and NVHH libraries against anti-
TirMEHEC.  
Growth curve of LB cultures of E. coli EcM1 cells carrying pAK-Not (empty vector) or plasmids of the 
pVHHA and pNVHH anti-TirMEHEC libraries. Procedure was carried out as described previously. 
 
Plating of the induced cultures to determine the number of colony forming units 
(CFU) per OD600 gave ~1.0x10
9 CFU/OD600 in the control (pAK-Not), ~ 0.9 x10
9 
CFU/OD600 in the anti-TirMEHEC VHHA library, and ~0.6x10
9 CFU/OD600 and anti-
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TirMEHEC NVHH library.  While for the anti-Fib libraries we found ~ 0.83 x109 
CFU/OD600 in VHHA library and ~0.8x10
9 CFU/OD600 in the NVHH library.  Hence, 
growth of bacteria is not overly affected due to expression or transport of the 
fusions, though expression of some NVHH fusions appear to slightly reduce the 
viability of E. coli cells when compared to control cultures, especially with the anti-
TirMEHEC library. Nevertheless, since the CFU/OD600 after expression of NVHH 
fusions remains within the same order of magnitude as the control, the diversity of 
the sdAb library is not compromised. Cell toxicity during the expression of Intimin 
constructs has been reported previously in some E. coli K-12 strains (Wentzel et al., 
2001). 
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Chapter 2: Selection and characterization of single domain Abs 
against TirMEHEC from immune libraries displayed on the surface of 
E. coli  
2.1 Translocated Intimin Receptor domain M (TirM) 
The translocated intimin receptor (Tir) of enteropathogenic and enterohemorrhagic 
Escherichia coli strains (EPEC and EHEC, respectively) is an important protein  for  
the infection of these enteric pathogens, which can result in severe diarrhea, 
hemorrhagic colitis and the life-threatening hemolytic uremic syndrome (in the case 
of EHEC). Tir is translocated through the bacterial type III secretion system  (Kenny 
et al., 1997; Gauthier and Finlay, 2003) into the host cell, where it becomes inserted 
in the plasma membrane through two hydrophobic helices that leave an 
extracellular region exposed to the surface of the host cell (Figure 16).  
 
Figure 16. The Intimin-Tir interaction between EPEC/EHEC bacteria and host cell plasma 
membrane. 
The model is based on structural data of the complex of the C-terminal fragment of intimin (domains 
D1, D2 and D3) and the extracellular domain of Tir (TirM) (Luo et al., 2000). Intimin is shown in green 
with its domains labelled. The transmembrane domain folds as a β-barrel (Fairman et al., 2012) and is 
inserted in the outer membrane of EPEC/EHEC.The Ig-like domains D0, D1, D2, and the lectin-like 
domain D3, which binds to the TirM, are shown as ovals. Tir is shown as a dimer (in pink and purple) 
in the host-cell membrane, with extracellular domain (residues 252-360) flanked by the two predicted 
transmembrane (TM) domains. The N-terminal domain of Tir anchors host cytoskeletal components 
(such as actin) that are needed to form the characteristic attaching and effacing (A/E) lesion on the 
host-cell surface upon bacterial adhesion. 
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This extracellular region of Tir, named TirM, which corresponds to amino acid 
residues 232-360 for Tir of EHEC, serves as anchor for the bacterial adhesin Intimin, 
responsible for the intimate attachment of these pathogens to the enterocyte. 
Intimin is an integral OM protein whose extracellular C-terminal domains are 
displayed on the surface of EPEC and EHEC bacteria and bind TirM region  (Kenny 
et al., 1997). The Intimin-Tir interaction ultimately leads to F-actin polymerization 
within the epithelial cell at the sites of bacterial attachment, and the formation of 
actin pedestals beneath the bacterium (Lai et al., 2013). It is postulated that 
blocking Intimin-Tir interaction could prevent the stable attachment of the bacteria 
to the intestinal epithelium and thus, reduce the infection process and the disease. 
2.2 Selection of single domain Abs against TirMEHEC by magnetic sorting of 
E. coli bacteria displaying the immune library 
E. coli EcM1 cells expressing VHHA and NVHH libraries were screened to isolate 
clones binding to TirMEHEC by magnetic cell sorting (MACS) (Figure 17).  
 
Figure 17. Schematic illustration of Magnetic cell sorting (MACS). 
General scheme summarizing the steps followed during MACS of an E. coli display library of sdAb 
with a biotinylated antigen. E. coli cells binding the biotinylated antigen are captured in a MACS 
column held in a magnet, while E. coli cells that do not bind the antigen are washed out of the 
column.  Elution of bound bacteria is done with fresh LB media upon column removal from the 
magnet. The CFU in the Washed and Bound fractions are determined by plating.   
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The MACS conditions for capturing E. coli cells expressing VHHA or NVHH fusions 
were established using biotin-labeled anti-E mAb. An initial input of 0.1 units of 
OD600 (~6-9x10
7 CFU of each culture) was incubated with 50-250 nM of biotinylated 
anti-E mAb allowing the recovery of a total of ~2-4x107 CFU in the Wash and Bound 
fractions. The Bound fractions contained ~95-99% of the CFU in the VHHA and 
NVHH libraries, and only ~0.2-0.5% in control E. coli cells with pAK-Not. Using these 
conditions, the VHHA and NVHH libraries were incubated with biotinylated TirMEHEC 
(250 nM) for the first selection step (MACS1) and ~0.3-0.6% of the total CFU from 
both libraries were collected in the Bound fractions (Table 5).  The colonies grown 
from the Bound fractions of each library were pooled independently, their plasmids 
purified and electroporated into fresh E. coli EcM1 cells to obtain VHHA and NVHH 
sublibraries (≥2x106 transformants). Next, the VHHA and NVHH sublibraries were 
subjected to a new round of selection with biotinylated TirMEHEC using conditions 
identical to those used in MACS1. Bacteria harvested from Bound fractions were 
pooled, their plasmids purified and transformed for the following rounds of MACS. 
Antigen concentration was reduced to 50 nM in the following MACS. The 
percentage of E. coli bacteria recovered in the Bound fractions showed a significant 
increase from the initial 0.3-0.6% to over 70% in MACS3 of NVHH and MACS4 of 
VHHA (Table 5), suggesting an enrichment of antigen binding clones in both libraries.  
 
Table 5. Summary of MACS with E. coli display libraries against TirMEHEC. _______________________________________________________________________________________________ 
Round  Antigen conc (TirMEHEC) VHHA library % NVHH library%  
MACS1  250 nM   0.3   0.6  
MACS2  250 nM   2.6            12.5   
MACS3    50 nM            12.5            75.6   
MACS4    50 nM            70.5               -   
(%): Percentage of bacteria in Bound fractions with reference to total bacteria in Wash+Bound 
fractions (ca. 1-5 x 107 CFU) 
 
Bacteria from the different rounds of selection were analyzed by flow cytometry to 
test their binding to biotinylated TirMEHEC (50 nM) (Figure 18), which demonstrated 
an enrichment of E. coli cells binding to TirMEHEC along the selection rounds, from 
~0.2 % positives in the original libraries to ~45% after MACS4 of the VHHA library 
and more than 75% positives after MACS2 and MACS3 of the NVHH library. No 
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significant binding to biotinylated BSA was detected by flow cytometry in these 
populations. The expression levels of the VHHA and NVHH fusions in the bacterial 
pools after the MACS steps were similar to those of the original libraries (data not 
shown). 
 
 
Figure 18. Magnetic cell sorting of VHHA and NVHH E. coli display libraries with biotinylated 
antigen, TirMEHEC. 
Fluorescent flow cytometry analysis of IPTG-induced E. coli EcM1 cells expressing VHHA (top panel) 
or NVHH (bottom panel) immune libraries, or their respective sublibraries enriched after the indicated 
round of MACS with biotinylated TirMEHEC. Histograms show the fluorescence intensity of bacteria 
incubated with biotinylated TirMEHEC and secondary Streptavidin-PE. 
 
 
Fifty colonies from the final round of selection of each library were randomly picked 
for plasmid isolation and DNA sequencing.  A VHH sequence, named as VTIR1, was 
found in all NVHH clones and in 36 VHHA clones, while the rest were different VHH 
sequences. Flow cytometry analysis confirmed the specific binding of biotinylated 
TirMEHEC (50 nM) by E. coli cells displaying VTIR1 fused to EhaA and Intimin β-
domains whereas these cells did not bind to biotinylated BSA (Figure 19A and 19B).  
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Figure 19. Binding of E. coli cells displaying selected clones from VHHA and NVHH libraries to 
biotinylated TirMEHEC. 
Fluorescent flow cytometry analysis of induced E. coli EcM1 cells bearing the indicated plasmids 
selected from (A) the VHHA library: pVTIR1A, pVTIR2A, pVTIR3A; and (B) from the NVHH library: 
pNVTIR1, pNVTIR4, pNVTIR5. Histograms show the fluorescence intensity of bacteria incubated with 
biotinylated antigens (TirMEHEC or BSA, as labeled) and secondary Streptavidin-PE. 
 
 
The MFI of E. coli cells displaying VTIR1 was higher in the NVTIR1 fusion than with 
VTIR1A fusion (Figure 20), although both were expressed at similar levels (Figure 20). 
We also conducted a flow cytometry screening of the remaining 14 non-VTIR1 clones 
from MACS4 of VHHA library, identifying three other VHH sequences that bound to 
biotinylated TirMEHEC, referred to as VTIR2, VTIR3, VTIR4 (Figure 20A, and data not 
shown). VTIR4 did not bind biotinylated BSA, but VTIR2 and VTIR3 clones exhibited 
non-specific binding to biotinylated BSA and were not further analyzed (Figure 19A 
and 19B). 
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Figure 20. E. coli cell surface display levels of VTIR1A and NVTIR1 clones. 
Fluorescent flow cytometry analysis of induced E. coli EcM1 cells expressing VTIR1A or NVTIR1 clone 
(as indicated). Control cells carried the empty vector pAK-Not. Histograms show the fluorescence 
intensity of bacteria stained with anti-E mAb and secondary anti-mouse IgG-Alexa 488.  
 
We sought for additional VHH sequences binding TirMEHEC in the NVHH library by 
screening 96 colonies picked randomly after the first round of selection (MACS1), in 
which a higher diversity of binders with low and high affinities are expected. PCR 
screening with a specific primer hybridizing the CDR3 of VTIR1 enabled us to identify 
17 VTIR1 clones out of these 96 colonies. This number fits with the percentage of 
clones recovered from this population after MACS2 (Table 5). Flow cytometry 
screening of the remaining clones allowed the identification of two additional VHH 
sequences that specifically bound biotinylated TirMEHEC, VTIR4 (2 clones), which was 
found previously in the VHHA library, and VTIR5 (1 clone). The MFI of binding of these 
clones to 50 nM biotinylated TirMEHEC was low compared to VTIR1  (Figure 19B) and 
increased at higher antigen concentrations (200 nM) (data not shown) suggesting 
that these clones had a lower affinity for TirMEHEC. The CDR3 amino acid sequences 
of the selected VHH clones are shown in Table 6. 
 
Table 6. CDR3 sequences of anti-TirMEHEC clones selected by E. coli display. 
 
Clone Name  Amino acid sequence of CDR3  β-domain system    
     VTIR1  GTAPYWHTPIPTLSEDKYFY   Neae, C-EhaA 
     VTIR2  GNSGSRGFDY    C-EhaA 
     VTIR3  AKGPRRCNQGFDY    C-EhaA   
     VTIR4  PDLSTNCDTVLTNSGALYNY  Neae, C-EhaA  
     VTIR5  PKYGGTWRWRVEEEKTTI   Neae    
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The VHHs encoded by VTIR1, VTIR4, VTIR5 and one unrelated VHH binding α-amylase 
as a control, were secreted into E. coli culture media as soluble fragments with the 
hemolysin system (Fernandez et al., 2000; Fraile et al., 2004) and used in ELISA 
against TirMEHEC and BSA. This experiment showed that soluble VTIR1, VTIR4, and 
VTIR5 sdAbs, bound specifically to TirMEHEC (Figure 21). According to ELISA data, 
VTIR1 was the clone with an apparent higher affinity, as could be also inferred from 
its strong enrichment in both the E. coli display libraries. 
 
 
Figure 21. ELISA of sdAbs selected by E. coli display against TirMEHEC.  
ELISA against TirMEHEC of sdAbs secreted into culture media as E-tagged HlyA fusions from the 
indicated VTIR clones and one a negative control (Vamy) (Fraile et al., 2004).  The plot shows the 
average OD values at 490 nm with standard error from duplicate experimental samples obtained with 
the secreted sdAbs at the indicated concentrations. ELISAs were developed with anti-E-tag mAb 
and anti-mouse-POD. ELISA signals against a control antigen (BSA) are subtracted from the 
represented values. 
2.3 Characterization of VTIR1 sdAb and determination of its affinity by 
Surface Plasmon Resonance (SPR) 
The VTIR1 clone was produced in the periplasm of E. coli WK6 cells as soluble sdAb 
with C-terminal His- and myc-tags and purified by metal-affinity chromatography 
followed by gel-filtration chromatography (Materials and Methods). As a control, 
Vgfp was also expressed and purified in the same manner. Both sdAbs behave as 
monomers with an apparent mass of ~15 kDa in gel filtration chromatography 
(Figure 22A).  The binding activity of the purified VTIR1 was confirmed in ELISA 
(Figure 22B).  
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Figure 22. Monomeric behaviour and binding activity of the purified sdAb, VTIR1. 
(A) Gel-filtration chromatograms of sdAbs VTIR1 and Vgfp purified from the periplasm of E. coli WK6 
cells (carrying the corresponding pCANTAB6-derivative) after a metal-affinity chromatography step.  
Gel-filtration chromatography was performed in a HiLoad 16/600 Superdex 75 column calibrated 
with protein markers (labeled in kDa) and Blue dextran (for exclusion volume Vo). Both sdAbs have 
major peaks of ~15 kDa corresponding to their monomeric forms.  (B) ELISA of purified monomeric 
VTIR1 and Vgfp (control) against TirMEHEC and BSA. The plot represents the OD values at 490 nm 
obtained with the indicated concentrations of sdAbs. ELISA developed with anti-myc mAb-POD as 
secondary. 
 
In order to determine the apparent equilibrium dissociation constant (KD) between 
VTIR1 and TirMEHEC, their interaction was studied in surface plasmon resonance (SPR) 
experiments with a Streptavidin (SA) sensor chip coated with biotinylated TirMEHEC 
(Materials and Methods). The change in resonance units (RU) was recorded with 
time at different concentrations of purified VTIR1 from 0.2 to 32 nM showing a clear 
binding to TirMEHEC that reached the steady state equilibrium in ~220 s for the two 
highest concentrations used, but not for the lower concentrations (Figure 23A). No 
binding was observed when Vgfp (40 nM) was flown over this sensor surface, or 
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when VTIR1 (40 nM) was flown over a SA cell lacking biotinylated TirMEHEC (data not 
shown).  Injection of buffer to evaluate the dissociation of VTIR1 (labeled with an 
arrow in Figure 23A) showed no loss of RU for > 200 s, indicating that VTIR1 
remained stably bound to TirMEHEC over long periods of time. Because of the very 
slow dissociation of VTIR1 from TirMEHEC, we were not able to calculate the value of 
KD directly from the curves. Hence, kinetic constants were calculated at a time point 
when the curves reached equilibrium (i.e. 220 s). From the graph, KD was calculated 
as 2.2 X 10-9 M (Figure 23B). 
 
 
Figure 23. Determination of the equilibrium dissociation constant (KD) of VTIR1 by SPR. 
(A) SPR sensograms monitoring real-time association and dissociation of purified sdAb VTIR1 (at the 
indicated concentrations) to biotinylated TirMEHEC immobilized onto a Streptavidin-SA sensor chip. 
The increase in resonance units (RU) is recorded along time (in seconds). Dissociation of VTIR1 is 
evaluated by injection of buffer at the time indicated with an arrow. (B) RU values at 220 seconds 
(labeled with a rectangle in A) are plotted versus the different concentrations of VTIR1. The curve was 
fitted by non-linear least squares regression. 
2.4 Estimation of the affinity of  VTIR1 by E. coli display 
Flow cytometry analysis under equilibrium conditions has been used to estimate the 
apparent KD of Abs and anticalins displayed on the surface of yeast and E. coli cells 
(Daugherty et al., 1998; Boder and Wittrup, 2000; Binder et al., 2010). Thus, we 
tested whether the affinity of VTIR1 could be estimated by flow cytometry analysis of 
E. coli cells with this sdAb on their surface and incubated with biotinylated TirMEHEC 
under conditions expected to be close to the equilibrium. We chose the Intimin 
display system given its superior MFI signals in flow cytometry with the antigen. E. 
coli EcM1 cells displaying NVTIR1 (~3x107 CFU) were incubated for 90 min  with a 
fixed amount of biotinylated TirMEHEC (2 pmols) in two-fold increasing volumes of 
PBS (from 0.1 to 2 ml) to reach a final concentration range from 20 nM to 1 nM.  
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After this incubation, cells were washed and labeled with Streptavidin-PE as 
previously described.  
 
The relative MFI of the cells was plotted against the antigen concentration used and 
the curve fitted by non-linear least squares regression, giving an estimated apparent 
KD of 1.7x10-9 M (Figure 24). This value was consistent with the apparent KD 
determined by SPR analysis (KD of ~2.2 x 10-9 M, Figure 23B), and indicates that the 
E. coli display systems could also be used to estimate the KD of selected sdAbs 
before purification. 
 
 
Figure 24. Estimation of the equilibrium dissociation constant (KD) of VTIR1 by E. coli display. 
The KD of VTIR1 was estimated by flow cytometry analysis of E. coli cells expressing NVTIR1 
incubated with different concentrations of biotinylated TirMEHEC under equilibrium conditions. The 
mean fluorescent intensities (MFI) of bacteria, after labeling with Streptavidin-PE, were plotted versus 
the concentration of TirMEHEC used in the assays. The curve was fitted by non-linear least squares 
regression. 
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Chapter 3: Selection and Characterization of high affinity single 
domain Abs against Human Fibrinogen from Immune libraries 
displayed on the surface of E. coli cells 
3.1 Human Fibrinogen (Fib). 
Fibrinogen (Fib, Factor I) is a 340 kDa glycoprotein produced by the liver and 
circulated in plasma at concentrations ranging between 1.5 and 4.5 mg/ml (Lowe et 
al., 2004). It plays a key role in the hemostatic system, being involved in the final 
step of blood coagulation. Abnormal Fib concentration in blood has been reported 
to be associated with cardiovascular diseases, venus thrombosis or myocardial 
infarction (Smith et al., 1998). There is also increasing evidence that Fib is a 
biomarker of oxidative stress (Selmeci et al., 2010) and metabolic syndrome (Onat 
et al., 2009) in human plasma. Lower protein concentrations indicate the risk of 
bleeding and maybe related to liver diseases, whereas higher Fib concentrations 
reveal an important risk for ischemic vascular or coronary accidents (Kamath and 
Lip, 2003), (Lowe et al., 2004), (Dudek et al., 2010). The structure of fibrinogen is 
illustrated in Figure 25. 
 
 
Figure 25. Structure of Fibrinogen. 
Fibrinogen is a dimeric glycoprotein composed of three pairs of peptide chains, i.e. α, β and 
γ chains. The two sub-units are composed of a D domain containing a globular region and an E 
domain, which contains a disulfide bond which links the two subunits. Fibrinogen is an important 
acute phase protein that is an important part of coagulation cascade of proteins. Thrombin rapidly 
hydrolyzes fibrinogen into fibrin and releases fibrinopeptides A and B. The fibrin is further stabilized 
by Factor XIIa, leading to aggregation of fibrin and blood platelets that block the damaged blood 
vessel preventing further bleeding. Plasmin is involved in Fibrin degradation into Fragment D and E. 
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Fib is also an important determinant of the metastatic potential of circulating tumor 
cells (Palumbo et al., 2000) and a prognostic blood marker for survival in patients 
with ovarian (Ma et al., 2007), (Polterauer et al., 2009) and gastric cancer (Yamashita 
et al., 2005).  
3.2 Selection of high affinity single domain Abs from the immune library 
against Fib by MACS 
Similar to previous work carried out with the immune libraries against TirMEHEC, 
MACS was used to isolate high affinity clones binding to biotinylated Fib from E. 
coli EcM1 bacteria expressing VHHA and NVHH libraries, generated from 
dromedaries immunized with purified Fib.  Initially, the VHHA and NVHH libraries were 
incubated with biotinylated Fib (250 nM) for the first selection step (MACS1) and 
~0.3-0.4% of the total CFU from both libraries were collected in the Bound fractions 
(Table 7).  The colonies grown from the Bound fractions of each library were pooled 
independently and their plasmids purified and electroporated into fresh E. coli EcM1 
cells to obtain VHHA and NVHH sublibraries (≥2x106 transformants). Next, the VHHA 
and NVHH sublibraries were subjected to a new round of selection with 100 nM 
biotinylated Fib and maintaining the other conditions identical to those used in 
MACS1. Bacteria harvested from Bound fractions were pooled, their plasmids 
purified and transformed for the following rounds of MACS. In total, 5 rounds of 
MACS were performed with both the NVHH and VHHA libraries.  
Table 7. Summary of MACS with E. coli display libraries against Fib. _______________________________________________________________________________________________ 
Round  Antigen conc (Fib)  VHHA library % NVHH library%  
MACS1  250 nM   0.3   0.4  
MACS2  100 nM   0.8             0.7   
MACS3  100 nM      1.7     3.3   
MACS4  100 nM    2.9   9.6 
MACS5  100 nM             26.1             24.5   
(%): Percentage of bacteria in Bound fractions with reference to total bacteria in Wash+Bound 
fractions (ca. 1-5 x 107 CFU) 
 
The percentage of E. coli bacteria recovered in the Bound fractions showed a very 
gradual increase from the initial 0.3-0.4% to over 50% in MACS5 of NVHH and VHHA 
(Table 7), suggesting an enrichment of antigen binding clones in both libraries. 
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Bacteria from the different rounds of selection were analyzed by flow cytometry to 
test their binding to biotinylated Fib (50 nM) (Figure. 26A and 26B), which 
demonstrated an enrichment of E. coli cells binding to Fib along the selection 
rounds, from ~0.25 % positives in the original libraries to ~40% and ~60% after 
MACS5 of the VHHA library and NVHH library respectively, with no significant binding 
to biotinylated BSA. The expression levels of the VHHA and NVHH fusions in the 
bacterial pools obtained after MACS was similar to those of the original libraries 
(Figure 26A and 26B).  
 
Figure 26. Magnetic cell sorting of VHHA and NVHH E. coli display libraries with biotinylated 
antigen, Fib. 
Fluorescent flow cytometry analysis of IPTG-induced E. coli EcM1 cells expressing (A) VHHA or (B) 
NVHH immune libraries, or their respective sub-libraries enriched after the indicated round of MACS 
with biotinylated Fib. Histograms show the fluorescence intensity of bacteria incubated with 
biotinylated Fib and secondary Streptavidin-PE or anti-E tag mAb and anti-mouse conjugated to 
Alexa 488 fluorophore. 
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Fifty colonies from the fifth round of MACS selection from both libraries were 
randomly picked for plasmid isolation and DNA sequencing. Upon DNA sequencing, 
three different VHH sequences, named as VFIB1, VFIB2 and VFIB3 were identified in 
both systems. The remaining clones were negative in binding to biotinylated 
fibrinogen (data not shown). The screening is summarized in Table 8. Flow 
cytometry analysis confirmed the specific binding of biotinylated Fib (50 nM) by E. 
coli cells displaying each of the three VHH sequences fused to the Intimin β-
domains, with negligible binding to biotinylated BSA. The MFI of VFIB1 and VFIB3 
were the best and at similar levels (Figure 27). 
 
Figure 27. Binding of E. coli cells displaying selected clones from VHHA and NVHH libraries to 
biotinylated Fib. 
Fluorescent flow cytometry analysis of induced E. coli EcM1 cells bearing the indicated plasmids 
selected from the NVHH library: pNVFIB1, pNVFIB2 and pNVFIB3. Histograms show the fluorescence 
intensity of bacteria incubated with biotinylated antigens (Fib or BSA, as labeled) and secondary 
Streptavidin-PE or anti-E mAb and secondary anti-mouse Alexa 488. 
 
Table 8. CDR3 sequences of anti-Fib clones selected by E. coli display. 
 
Clone Name  Amino acid sequence of CDR3  Display system    
                         Neae           C-EhaA 
     VFIB1  RWGWASSSNWYDMGKYNY  15/50  09/50 
     VFIB2  RCAPES     21/50  26/50 
     VFIB3  KYYRSCTSLGDYRN    06/50  03/50 
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3.3 Purification of VFIB1 and VFIB2 VHHs from the periplasm of E. coli as 
fusions to MBP 
The two more frequent clones against Fib isolated by E. coli display, VFIB1 and VFIB2, 
were initially produced in the periplasm of E. coli WK6 cells as soluble VHHs with C-
terminal His6- and myc-tags, but poor yields were attained (~0.1-0.2 mg/L; data not 
shown). Similar problems of variability in protein expression have been previously 
reported during the production of VHHs against methotrexate, (Alvarez-Rueda et al., 
2007). Another common issue is that the single IMAC step is generally not sufficient 
to avoid the presence of protein contaminants in VHH preparations, thus requiring 
further purification by less efficient chomatographic steps (e.g. gel filtration, ion-
exchange). Hence, in order to circumvent these issues, we developed a purification 
method for VHHs based on their fusion to the E. coli maltose binding protein (MBP) 
in the N-terminus and a His6-tag in the C-terminus. 
3.3.1 Expression and solubility of the MBP-VHHHis6 fusions 
In order to investigate whether fusion to MBP could have a positive effect on 
expression levels of VHHs and on their purification from the E. coli periplasm, we 
constructed an expression vector, named pMAL1-VHH (Figure 28). 
 
 
Figure 28. Schematic representation of protein expression vector. 
The pMALp2E plasmid vector (New England Biolabs) was modified to include the PreScission 
protease cleavage site and DNA restriction enzyme sites (EcoRI, SfiI, NotI, HindIII) for cloning of the 
VHH to the C-terminal end of MBP. This modified vector, pMAL1- VHH also contains the His6 and 
myc tags for purification and detection respectively.  
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pMAL1-VHH is based on the pMAL-p2E backbone (New England Biolabs), and 
contains in addition, the cleavage site for the site-specific protease PreScission 
(LEVLFQ/GP) in the linker connecting MBP with the VHH, a C-terminal His6 and myc 
tags. The MBP-fusions are under the control of the IPTG-inducible Ptac promoter, 
while the vector also encodes the LacI repressor and contains unique SfiI and NotI 
restriction sites flanking the VHH sequence encoding the VHH. Three characterized 
VHH genes with different complementarity determining region (CDR) sequences, 
encoding VHHs that specifically recognized human fibrinogen (VFIB1 and VFIB2), or 
GFP (VGFP) were cloned and the corresponding pMAL1-VHH derivative was 
generated.  Expression of MBP-VHHHis6 fusions was initially tested in E. coli BL21 
strain (Studier and Moffatt, 1986) but high proteolysis of the full-length fusions was 
observed (data not shown). Hence, we tested protein production in an E. coli strain 
deficient in several periplasmic proteases, E. coli HM140 (Meerman and Georgiou, 
1994), and high-level accumulation of the full-length MBP-VHHHis6 (~60 kDa) was 
obtained after 3 h induction at 30ºC with 0.3 mM IPTG (Figure 29A).  
 
Figure 29. Induction and solubility of the MBP-fusions. 
 (A) 10% SDS-PAGE gel loaded with pre- and post-induction Whole Cell Extract (WCE) samples to 
check the induction and expression of the MBP-fusion protein. The MBP-VHH fusion has a size of 
about 60 kDa (as labelled with the arrow). (B) 10% SDS-PAGE gel loaded with (Lane 1) Whole Cell 
Extract (WCE) obtained after lysis of IPTG-induced E. coli HM140 cells expressing the MBP fusion 
proteins. The WCE sample was centrifuged at 20000 X g for 60 mins in a tabletop centrifuge, and the 
pellet after centrifugation (Insoluble fraction, Lane 2) and the supernatant (Soluble fraction, Lane 3) 
were loaded onto the 10% SDS-polyacrylamide gel. The MBP-VHH fusions are found in the soluble 
fraction of the WCE after centrifugation. Mass of protein standards is shown on the left (in kDa). 
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Approximately 15-20 mg of MBP-VHHHis6 fusions were produced per litre of induced 
culture in shake flasks with a final OD600 ~1.0. Importantly, in all cases the majority 
of the accumulated MBP-VHHHis6 fusion remained in the soluble fraction after cell 
lysis and high-speed centrifugation (20000 xg, 1 h), as indicated by SDS-PAGE 
analysis (Figure. 29B). 
3.3.2 Purification of MBP-VHHHis6 fusions and antigen binding activity 
The supernatants containing the MBP-VHHHis6 fusions obtained after high-speed 
centrifugation of the cell lysate were passed through a chromatography column 
packed with amylose resin and the bound proteins were eluted with 10 mM maltose 
(Figure 30A). SDS-PAGE analysis showed a pre-dominant band of ~60 kDa in the 
eluted fractions that corresponds to MBP-VHHHis6 fusions (Figure 29A). The fractions 
containing the MBP-VHHHis6 fusions were pooled and loaded onto cobalt-containing 
columns for IMAC. Bound MBP-VHHHis6 fusions were eluted with 150 mM imidazole, 
pooled and analyzed by SDS-PAGE showing the presence of a single major band 
corresponding to the full-length MBP-VHHHis6 fusions (Figure 30B). In all cases, a 
final yield of ~12-16 mg of purified MBP-VHHHis6 fusions were obtained per L of 
induced culture (Table 9). 
 
ELISA was subsequently used to test the antigen-binding activity of the purified 
MBP-VHHHis6 fusions and different concentrations of the purified MBP-VHHHis6 
fusions were incubated with their respective antigens (GFP or Fib) and with a 
negative control antigen (BSA). Bound MBP-VHHHis6 fusions were developed with 
anti-c-myc-mAb-POD. The generated binding curves (Figure 30C) demonstrate that 
these fusions recognized their specific antigens, indicating that the presence of 
MBP did not prevent the binding of the antigen by the VHH, which is in agreement 
with previous reports that MBP-scFv fusions maintain the antigen binding activity of 
scFvs (Bach et al., 2001). Thus, our data showed that MBP-VHHHis6 fusions can be 
purified in high yields by two steps of affinity chromatography and they can be 
directly used for antigen binding or applications thereof. 
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Figure 30. Purification of the MBP-fusions by Amylose affinity chromatography and their 
functional analysis by ELISA. 
(A) Chromatogram of the purification of MBP-fusion proteins by Amylose Affinity Chromatography. 
The flowthrough fraction contains non-specific proteins and other impurities that do not bind the 
column and the elute fraction contains the purified MBP-VHH fusions. (B) 10% SDS-PAGE gel loaded 
with each of the three purified MBP-VHH fusions i.e. MBP-VFIB1 and MBP-VFIB2 are the fusions of 
MBP with either of two different VHHs against human fibrinogen and MBP-VGFP is a fusion of MBP 
with a VHH against GFP isolated from VHH libraries against GFP. (C) ELISA to determine the antigen 
binding activity of the purified MBP-VHH fusions. Different wells were coated with 5 µg/ml of GFP 
and human fibrinogen (positive antigens) or BSA (negative control) proteins, followed by addition of 
MBP-VHH solution (0.05-100 nM) to all coated wells. The presence of bound MBP-VHH fusion was 
detected by incubation with anti-c-myc-POD and development using a chromgenic substrate. The 
absorbance values reflect the specific binding of each of the MBP-VHHs to their respective antigens 
and have been adjusted by subtraction of the respective blank values (non-specific binding of each 
MBP-VHH to BSA). 
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3.3.3 Purification of monomeric VHHHis6 from MBP-VHHHis6 fusions 
To purify monomeric VHHHis6s free of MBP, we evaluated the following purification 
scheme summarized in Figure 31.  
 
 
Figure 31. Expression and purification of VHHs in E. coli. 
The scheme followed for purification of VHHs from MBP-VHH fusion proteins is illustrated.  
 
Briefly, fractions containing the MBP-VHHHis6 fusions eluted from the amylose resin 
were dialyzed to remove maltose and digested with the PreScission protease at 4 
ºC for 16 h. The products of the proteolysis were analyzed on a 12% SDS-PAGE gel 
(Figure 32A). About 80-90% of the initial full-length MBP-VHHHis6 fusion present in 
the reaction was digested into free MBP (~45 kDa) and the corresponding VHHHis6 
(~17 kDa) in all cases. The proteolytic products were subsequently loaded onto an 
amylose resin in order to capture the undigested MBP-fusion and free MBP, while 
collecting the VHHHis6 in the flow-through.  The flow-through fractions for each of the 
three VHHs were loaded onto a cobalt-containing column for IMAC. PreScission 
protease and residual free MBP, along with other impurities, were washed from the 
IMAC column and the purified VHHHis6 clones were eluted with 150 mM imidazole 
(Figure 32B). Some residual amounts of the full-length MBP-VHHHis6 fusion could be 
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detected in some cases, due to the presence of His6-tag. The final yields of purified 
VHHHis6 were ~2-3 mg per L of induced culture (Table 9). 
 
 
Figure 32. Protease digestion of MBP-VHH fusions, Immobilized Metal Affinity chromatography 
(IMAC) and Gel filtration. 
 
A) SDS-PAGE of MBP-VHH fusions digested overnight with PreScission protease at 4ºC for 16 h. 
Upon observation of the gel, it can be inferred that majority of the MBP-VHH fusion was digested and 
separated from the VHH. Mass of protein standards is shown on the left (in kDa). (B) IMAC 
purification of VHH using Talon resin. The chromatogram of the chromatographic run is illustrated in 
this figure. Residual impurities like MBP and PreScision protease do not bind to the Talon resin and 
are found in the flowthrough, while the VHH binds to the resin and is eluted with 200 mM imidazole in 
the elution peak. (C) The VHH was loaded on to a Gel filtration column to analyze the protein for 
presence of multimers or dimers and separate the monomeric VHH from other forms. The exclusion 
volume (Vo) and the molecular weights of the gel filtration standards are indicated (in kDa). Peak 1 
corresponds to the VHH in monomeric form with a molecular weight of ∼16 kDa. 
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Table 9. Protein yields after purification from the periplasm of E. coli HM140.  
             
Fusion protein MBP- VHHHis6 (mg/litre culture) MBP-VHHHis6 (mg/litre culture) 
   MBP-VHH1    12.5    2.2 
   MBP-VHH2    16.3    3.2 
   MBP-VHH3    14.6    2.5    
 
Gel filtration chromatography through a precalibrated HiLoad 16/600 Superdex 75 
pg column was used to analyze the composition of the eluted VHHHis6 after IMAC 
and to purify the fractions corresponding to monomeric VHHHis6. In each of the three 
cases, ≥95% of the protein eluted corresponded to the monomeric VHHHis6 as 
depicted by the single major peak with an apparent molecular weight of ca. 15 kDa 
obtained by gel filtration (Figure 32C). 
 
Further, each purified monomeric VHHHis6 (namely VFIB1, VFIB2 and VGFP) was 
analyzed by SDS-PAGE and revealed a single protein band with molecular weights 
of ca. 15 -17 kDa (Figure 33A) and was found to be functional by ELISA (Figure 
33B).  
 
 
Figure 33. Monomeric VHHs and assay of functional activity  by ELISA. 
(A) Monomeric VHHs after gel filtration were loaded on to a 12% SDS-polyacrylamide gel and stained 
with Coomassie Brilliant Blue solution. The purified VHHs (Lane 1 and Lane 2 – VHHs against 
Fibrinogen, Lane 3 – VHH against GFP) have a molecular weight between 15 and 18 kDa. Mass of 
protein standards is shown on the left (in kDa). (B) ELISA to determine the antigen binding activity of 
purified monomeric VHHs. Wells were coated with 5 mg/ml of GFP, Human Fibrinogen (positive 
antigen) or BSA (negative control) proteins, followed by addition of VHH solution (0.05-100 nM) to the 
wells. The signal was developed by incubation with anti-c-myc-POD. 
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3.4 Determination of the affinity of VFIB1 and VFIB2 by Surface Plasmon 
Resonance (SPR) 
In order to determine the apparent equilibrium dissociation constant (KD) of VFIB1 
and VFIB2 against Fib, their interaction was studied by SPR experiments with a 
Streptavidin (SA) sensor chip coated with biotinylated Fib (Materials and Methods). 
The change in resonance units (RU) was recorded with time at different 
concentrations of purified VFIB1 (from 2.5 to 40 nM) or VFIB2 (from 5 to 80 nM), and 
showed clear binding to Fib that reached the steady state equilibrium in ~180s 
(Figure 34A and 34B). No binding was observed when Vgfp (40 nM) was flown over 
this sensor surface, or when VFIB1, VFIB2 (40 nM) was flown over a SA flow-cell 
lacking biotinylated Fib (data not shown).  Injection of buffer to evaluate the 
dissociation of VFIB1 or VFIB2 showed gradual loss of RU with time and the kinetic 
constants (kon and koff) were calculated from the sensograms. VFIB1 had a KD of 3.2 x 
10-9 M, with kon = 6.62 x 10
5 Ms-1 and koff = 2.1 x 10
-3 s-1. VFIB2, on the other hand, 
had a KD of 24.7 x 10
-9 M, with kon = 1.02 x 10
6 Ms-1 and koff = 2.52 x 10
-2 s-1. 
 
 
 
Figure 34. Determination of the equilibrium dissociation constant (KD) of clones VFIB1 and VFIB2 
by SPR. 
SPR sensograms monitoring real-time association and dissociation of purified sdAbs (A) VFIB1 and 
(B) VFIB2 (at the indicated concentrations) to biotinylated Fib immobilized onto a Streptavidin-SA 
sensor chip. The increase in resonance units (RU) is recorded along time (in seconds). Dissociation 
of VFIB1 and VFIB2 was evaluated by injection of buffer. The curve was fitted by non-linear least 
squares regression. 
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3.5 Estimation of the affinity of VFIB1 and VFIB2 by E. coli display 
Flow cytometry analysis was used to estimate the apparent KD of the selected VFIB 
sdAbs as previously performed with the VTIR1 sdAb. It was known that the sdAbs, 
VFIB1 had higher apparent affinity than VFIB2, therefore the final concentration range 
of biotinylated Fib in the assay for VFIB1 was maintained between 30 nM and 0.3 
nM, while in the case of VFIB2, this range was between 300 nM and 3 nM. Briefly, E. 
coli cells (~3x107 CFU) with the respective sdAb on their surface were incubated 
with a fixed amount of biotinylated Fib (2 pmols) for 90 mins in two-fold increasing 
volumes of PBS (from 0.01 to 2 ml) to reach the respective final concentration 
ranges (as mentioned above).  After this incubation, cells were washed and labeled 
with Streptavidin-PE as previously described.  
 
The relative MFI of the cells was plotted against the antigen concentration used and 
the curve fitted by non-linear least squares regression, giving an estimated apparent 
KD of 3 x10
-9 M for VFIB1 and 35 x10-9 M for VFIB2 (Figure 35A and 35B). These values 
were consistent with the KD determined by SPR (Figure 34A and 34B). 
 
 
 
Figure 35. Estimation of the equilibrium dissociation constant (KD) of clones VFIB1 and VFIB2 
against Fib by E. coli display. 
The KD of the selected clones (as indicated) was estimated by flow cytometry analysis of E. coli cells 
expressing NVFIB1 or NVFIB2 incubated with different concentrations of biotinylated Fib under 
equilibrium conditions. The mean fluorescent intensities (MFI) of bacteria, after labeling with 
Streptavidin-PE, were plotted versus the concentration of Fib used in the assays. The curve was 
fitted by non-linear least squares regression. 
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Chapter 4: Cell Selection and characterization of high affinity single 
domain Abs against human EGFR from immune libraries displayed 
on the surface of E. coli cells 
4.1 Epidermal Growth Factor Receptor (EGFR) 
The epidermal growth factor receptor (EGFR/Her1/ErbB1) is a transmembrane 
receptor belonging to the ErbB family of tyrosine kinases and is implicated in many 
human cancers (especially on squamous cancer cells), being an important target for 
several classes of therapeutic agents, including Ab-based drugs. These receptors 
are abnormally expressed in many epithelial tumors such as colorectal, lung, brain, 
breast, head and neck tumors etc (Gullick, 1991; Baselga and Arteaga, 2005; Huang 
et al., 2009) and influence their growth and survival in malignant states (Zaczek et 
al., 2005). The receptor comprises a transmembrane domain, an extracellular 
ligand-binding domain and an intracellular domain with tyrosine kinase activity 
(Figure 36A). Several mammalian ligands are known to activate EGFR, including 
EGF, transforming growth factor-α (TGF-α), heparin-binding EGF-like growth factor 
(HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR) and epigen (EPI). 
EGFR signalling promotes angiogenesis, proliferation, invasion and metastasis of 
the tumor cells.  
 
It is well established that Ab binding to the extracellular domain of EGFR can inhibit 
ligand-induced receptor activation and tumor growth (Sato et al., 1983; Gill et al., 
1984). Various EGFR agents have been developed as anti-cancer drugs, for 
example, cetuximab, panitumumab (both are mAbs), gefitinib and erlotinib (small-
molecule inhibitors). The mAbs target the extracellular domain of the receptor and 
inhibit ligand-dependent EGFR signal transduction, while the small-molecule 
inhibitors target the intracellular tyrosine kinase. Inactive EGFR can exist as both 
monomers and dimers, suggesting that the mechanism regulating EGFR activity 
may be subtle. Dimerization-driven activation of the intracellular kinase domains of 
the epidermal growth factor receptor (EGFR) upon extracellular ligand binding is 
crucial to cellular pathways regulating proliferation, migration, and differentiation. 
Molecular dynamic simulations of the membrane with the embedded EGFR 
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(Arkhipov et al., 2013) suggest that in ligand-bound dimers, the extracellular 
domains assume conformations favoring dimerization of the transmembrane helices 
near their N termini, dimerization of the juxtamembrane segments, and formation of 
asymmetric (active) kinase dimers. In ligand-free dimers, by holding apart the N 
termini of the transmembrane helices, the extracellular domains instead favor C-
terminal dimerization of the transmembrane helices, juxtamembrane segment 
dissociation and membrane burial, and formation of symmetric (inactive) kinase 
dimers (Figure 36B). 
 
Figure 36. Schematic of EGFR and the states in which it exists. 
(A) Scheme of EGFR domains (left), showing extracellular domain, transmembrane (TM) α-helix, 
juxtamembrane domains A&B, kinase domain, and C-terminal tail. (B) EGFR is present in the 
monomeric form or as a pre-formed dimer (inactive). Encounter of its ligand i.e. EGF, leads to 
phosphorylation of its C-terminal tail (active dimer) (Arkhipov et al., 2013), initiation of signalling 
cascades and stimulation of cell cycle machinery. Leads to secretion of growth, angiogenic and 
motility factors 
 
4.2 Construction of immune sdAb library against Human EGFR 
An immune sdAb library against Human EGFR cloned in a phage display vector 
(Roovers et al., 2007) was a kind gift from Dr Rob Roovers and Paul van Bergen en 
Henegouwen, University of Utrecht, Netherlands.  This library contains ca. 107 
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independent clones and was constructed from VHH gene segments amplified from 
lymphocytes isolated from two llamas (Llama glama) immunized with intact human 
A431 cells, which overexpress EGFR (ca. 2x106 molecules of EGFR/cell). . The VHH 
repertoire of this library was cloned into the SfiI and NotI sites of the pNeae2 vector 
and transformed into EcM1 cells for E. coli display. A library of ~2x107 independent 
clones was generated. 
4.3 Selection of high affinity sdAbs from the anti-EGFR immune  library by 
MACS  
To test the E. coli display NVHH library anti-EGFR we employed first MACS with 
purified rhEGFR-Fc, a recombinant protein carrying the extracellular domain of 
human EGFR fused to an Ig Fc region.   Similar to previous selections with TirM and 
Fib, 2x108 bacteria were incubated with biotinylated rhEGFR-Fc (100 nM) for the first 
selection step (MACS1) and ~0.6-0.7% of the total CFU were collected in the 
Bound fraction (Table 10). The colonies grown from the Bound fraction were pooled, 
their plasmids purified and electroporated into fresh E. coli EcM1 cells  (≥107 
transformants). This sublibrary was subjected to a new round of selection with 100 
nM biotinylated rhEGFR-Fc under identical conditions.  
Table 10. Summary of MACS with E. coli display libraries against rhEGFR. _______________________________________________________________________________________________ 
Round   Antigen conc (rhEGFR-Fc)  NVHH library%   
MACS1   100 nM        0.3    
MACS2   100 nM           2.6     
 
(%): Percentage of bacteria in Bound fractions with reference to total bacteria in Wash+Bound 
fractions (ca. 1-5 x 107 CFU) 
 
The percentage of E. coli bacteria recovered in the Bound fractions increased to 
2.6% in MACS2  (Table 10) and were analyzed by flow cytometry to test their 
binding to biotinylated rhEGFR-Fc (50 nM) (Figure 37), which demonstrated an 
enrichment of E. coli clones binding to rhEGFR-Fc with more than 70% positives 
after MACS2. No significant binding to biotinylated BSA was detected by flow 
cytometry in these populations. The expression levels of the NVHH fusions in the 
bacterial pools obtained after MACS were similar to those in the original library 
(Figure 37). 
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Figure 37. Magnetic cell sorting of NVHH E. coli display libraries with biotinylated rhEGFR-Fc 
antigen. 
Fluorescent flow cytometry analysis of IPTG-induced E. coli EcM1 cells expressing NVHH immune 
libraries, or their respective sub-libraries enriched after the indicated round of MACS with 
biotinylated rhEGFR-Fc. Histograms show the fluorescence intensity of bacteria incubated with 
biotinylated rhEGFR-Fc and secondary Streptavidin-PE or anti-myc tag mAb and anti-mouse 
conjugated to Alexa 488 fluorophore. 
4.4 Direct cell selection of high affinity sdAbs against EGFR using E. coli 
display. 
We wanted to determine whether E. coli display could allow the direct selection of 
sdAbs from immune libraries against EGFR on live tumor cells overexpressing EGFR 
on its surface, instead of purified recombinant EGFR protein, previously used during 
MACS. Hence, we designed a simple cell selection (CellS) procedure consisting of 
an initial incubation step of the E. coli display library with a monolayer of the murine 
tumor cell line, NIH-3T3 2.2, which lacks expression of endogenous EGFR. This 
allows substractive selection of binders recognizing other cell surface antigens. 
Next, clones that did not bind NIH-3T3 2.2 cells were incubated with a monolayer of 
the murine tumor cell line HER14, which is a stably transfected NIH-3T3 2.2 clone 
expressing hEGFR (Honegger et al., 1987). Bacteria binding to HER14 were 
recovered on LB plates for plasmid isolation and subjected to subsequent rounds of 
selection. A schematic illustration of the methodology proposed is shown in Figure 
38.  
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Figure 38. Direct selection of NVHH E. coli display libraries on cells. 
E. coli cells are intially bound to eukaryotic cells not expressing EGFR i.e. NIH-3T3 2.2, and any 
bacteria binding non-specifically to these cells are removed. The bacteria that do not bind are 
recovered and incubated with eukaryotic cells that express EGFR i.e. HER14. The HER14 cells are 
washed to remove non-specific or loosely bound E. coli cells, followed by lysis of eukaryotic cells 
and elution of bound bacteria. The CFU of bound bacteria in the cell lysate is determined by plating. 
 
Both cell lines were seeded in 6-well cell culture plates to attain a confluency of 
50% in 24 h (≈6X105 cells per well). Firstly, depletion of bacteria displaying VHH 
clones binding to cell surface antigens but not to EGFR was carried out by 
incubation of induced bacteria (≈6X107) with NIH-3T3 2.2 cells (EGFR-) at a MOI of 
≈100, for 1h at 37ºC. Secondly, the bacteria that were not bound to the negative cell 
line were recovered and incubated with HER14 cells (EGFR+) for 15 mins at 37ºC. 
Further, the cells were washed three times with HBSS to remove unbound bacteria 
and lysed by addition of HBSS supplemented with 0.2% SDS and 0.1% DNAse.  
The resulting cell lysate containing bacteria was plated. 
 
The colonies grown in plates were pooled, their plasmids purified and 
electroporated into fresh E. coli EcM1 cells.  The sublibrary was subjected to a 
additional round of CellS with NIH-3T3 2.2 and HER14 cell lines using identical 
conditions. The percentage of E. coli bacteria recovered in the HER14 cell-bound 
fractions showed an increase from the initial 0.3% in CellS1 to 1.2% in CellS2 
(Table 11), suggesting an enrichment of clones binding specifically to HER14. 
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Table 11. Summary of Cell selections with NVHH E. coli display library against rhEGFR. _______________________________________________________________________________________________ 
Round  Bacteria in input    Bacteria in output        % bacteria recovered  
CellS1   6 x 107   2 x 105           0.3 
CellS2   6 x 107           7 x 105           1.2   
A total of 6x105 cells were seeded in 6 well culture plates. Bacteria were added at a MOI =100 
 
Bacterial pools from each of the different rounds of cell selection were analyzed by 
flow cytometry to test their binding to biotinylated rhEGFR (50 nM) (Figure 39), 
which demonstrated an enrichment of E. coli cells binding to rhEGFR along the 
selection rounds, from ~0.2 % positives in the original libraries to ~35% after 
CellS2. No significant binding to biotinylated BSA was detected by flow cytometry 
in these populations. The expression levels of the NVHH fusions in the bacterial 
pools obtained after cell selection was similar to those of the original libraries 
(Figure 39). 
 
 
 
Figure 39. Flow cytometry analysis of anti-EGFR NVHH E. coli display libraries selected on 
cells. 
Fluorescent flow cytometry analysis of IPTG-induced E. coli EcM1 cells expressing NVHH immune 
libraries, or their respective sub-libraries enriched after the indicated round of cell selection with 
biotinylated rhEGFR. Histograms show the fluorescence intensity of bacteria incubated with 
biotinylated rhEGFR-Fc (50 nM) and secondary Streptavidin-PE or anti-myc tag mAb and anti-mouse 
conjugated to Alexa 488 fluorophore. 
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Ninety-six colonies from the second round of selection of the NVHH library by MACS 
(i.e MACS2) were randomly picked for plasmid isolation and DNA sequencing. In the 
screening of the MACS2, a VHH sequence, named as VEGFR1, was found in 72 NVHH 
clones, while other clones, namely VEGFR2 (10 clones), VEGFR3 (1 clone), VEGFR4 (3 
clones) and VEGFR5 (1 clone) were also found, the rest being non-EGFR binding VHH 
sequences.  
 
Similarly, ninety-six clones from CellS2 were screened by visual observation under a 
light microscope of their specific binding to HER14 cells (EGFR+), but not to NIH-
3T3 2.2 cells (EGFR-). Briefly, induced bacteria were added to wells containing 
either HER14 cells or NIH-3T3 2.2 cells at a MOI of 100 and the infection was 
monitored after 20 minutes by visual inspection in an inverted microscope. Clones 
that did not bind either cell line were classified as “Non-binders”, those that bound 
both NIH-3T3 2.2 cells and HER14 cells were classified as “non-specific binders” 
and those that bound only HER14 cells, but not NIH-3T3 2.2 cells were called 
“specific binders”. Out of the 96 clones screened by this method, 45 clones were 
non-binders, 26 clones were non-specific binders and 25 clones were specific 
binders. DNA sequences of all 25 specific binders were isolated and sequenced. 
Like previous screening of MACS2 population, VEGFR1 was found 18 times and was 
the major clone. VEGFR2 (3 clones), VEGFR4 (2 clones) were also found, while one new 
clone, VEGFR6 (2 clones) was also identified. The CDR3 sequences of all identified 
clones are illustrated in Table 12. 
 
Table 12. CDR3 sequences of anti-EGFR clones selected by E. coli display. 
 
Clone Name  Amino acid sequence of CDR3  Selection system   
                         MACS             CellS  
     VEGFR1  DKWSSSRRSVDYDY   72/96  18/96 
     VEGFR2  TYNPYSRDHYFPRMTTEYDY  10/96  03/96 
     VEGFR3  RYSDVIFTLPERYAY    01/96        - 
     VEGFR4  STYSRDSVFTKWANYNY   03/96  02/96 
     VEGFR5  GPILGSSESYRSSRRYAY   01/96      - 
     VEGFR6  DLNFIGIVTTTSEKYDY        -  02/96  
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4.5  Binding of selected clones to EGFR+ tumor cells by immunofluorescence 
microscopy 
All anti-EGFR clones isolated by E. coli display were further characterized for their 
specific binding to HER14 cells (EGFR+) but not to NIH-3T3 2.2 cells (EGFR-) by 
immunofluorescence microscopy, staining the samples with DAPI (nuclei) and 
fluorescent antibodies against EGFR and E. coli. This experiment revealed that all 
positive anti-EGFR E. coli obtained by MACS and CellS (Table 12) bound 
specifically to HER14 cells but not to NIH-3T3 2.2 cells (Figures 40 and 41), while 
one non-specific clone (number 37 from CellS, VCLONE37) from CellS screening 
bound to both cell lines and a negative control E. coli displaying NVFIB1 bound to 
neither of the cell lines (Figure 40). 
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Figure 40. Bright field and immunofluorescence microscopy images of E. coli bacteria 
displaying the indicated VHH clone to HER14 and NIH-3T3 2.2 cells. 
These images show the binding specificity of E. coli bacteria displaying the selected anti-EGFR 
clones VEGFR1 and VEGFR2, to HER14 and not to NIH-3T3 2.2 cells. A negative clone (VFIB1) and a 
non-specific clone from CellS (VCLONE 37) are also included as controls. Bacteria are labelled with 
anti-E. coli (red), EGFR is labelled with anti-EGFR mAb (green), DNA and cell nuclei labelled with 
DAPI (blue).  
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Figure 41. Bright field and immunofluorescence microscopy images of E. coli bacteria 
displaying the indicated VHH clone to HER14 and NIH-3T3 2.2 cells (continued). 
These images show the binding specificity of E. coli bacteria displaying VEGFR3, VEGFR4, VEGFR5 and 
VEGFR6 to HER14 and not to NIH-3T3 2.2 cells. Samples stained as in Figure 39. 
 
4.6 Binding of selected clones to biotinylated rhEGFR-Fc by flow cytometry. 
Flow cytometry analysis confirmed the specific binding of biotinylated rhEGFR-Fc 
(50 nM) by E. coli cells displaying each of the six VHH sequences, with negligible 
binding to biotinylated BSA. The MFI of VEGFR1 and VEGFR2 was the best and at 
similar levels (Figure 42A), which suggested that these clones had a high apparent 
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affinity for rhEGFR, while the MFI of VEGFR3-6 was found to be lower, suggesting that 
it had a lower apparent affinity for rhEGFR. An overlay of the binding of all selected 
clones to rhEGFR in flow cytometry is illustrated in Figure 42B. 
 
Figure 42. Binding of E. coli cells displaying selected clones from anti-EGFR NVHH libraries to 
biotinylated rhEGFR-Fc. 
(A) Fluorescent flow cytometry analysis of induced E. coli EcM1 cells bearing the indicated plasmids 
selected from the anti-EGFR NVHH library. (B) Overlay of histograms of binding of the selected 
clones to biotinylated EGFR. Histograms show the fluorescence intensity of bacteria incubated with 
biotinylated antigens (rhEGFR or BSA, as labeled) and secondary Streptavidin-PE. 
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4.7 Estimation of the affinity of VEGFR1 and VEGFR2 by E. coli display 
Flow cytometry analysis was used to estimate the apparent KD of two VEGFR clones 
with highest binding signals. The final concentration range of biotinylated rhEGFR-
Fc in the assay for was between 100 nM and 0.8 nM. Briefly, E. coli cells (~3x107 
CFU) with the respective sdAb on their surface were incubated with a fixed amount 
of biotinylated rhEGFR-Fc (1 pmol) for 90 mins in two-fold increasing volumes of 
PBS (from 0.01 to 2 ml) to reach the desired final concentration range (as above).  
After this incubation, cells were washed and labeled with Streptavidin-PE as 
previously described. The relative MFI of the cells was plotted against the antigen 
concentration used and the curve fitted by non-linear least squares regression, 
giving an estimated apparent KD of 30 x10
-9 M for VEGFR1 (Figure 43A) and 12 x10-9 
M for VEGFR2 (Figure 43B). 
 
 
 
Figure 43. Estimation of the equilibrium constant (KD) of VEGFR1 and VEGFR2 by E. coli display. 
The KD of the selected clones (as indicated) was estimated by flow cytometry analysis of E. coli cells 
expressing NVEGFR1 or NVEGFR2 incubated with different concentrations of biotinylated EGFR (0.8-
100 nM) as specified, under equilibrium conditions. The mean fluorescent intensities (MFI) of 
bacteria, after labeling with Streptavidin-PE, were plotted versus the concentration of EGFR used in 
the assays. The curve was fitted by non-linear least squares regression.  
4.8 Binding of the selected clones to EGFR in the presence of EGF 
All the clones selected by E. coli display were further characterized for their ability to 
bind EGFR in the presence of EGF using flow cytometry. It was observed that 
clones VEGFR2, VEGFR3, VEGFR4, VEGFR6 and to a lesser extent VEGFR1, had reduced 
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binding signals to rhEGFR-Fc (50 nM) when 25 µM EGF was present, while the 
binding of VEGFR5 was almost the same in the presence or absence of EGF (Figure 
44). 
 
 
 
Figure 44. Flow cytometry analysis of binding to EGFR by the clones selected by E. coli display 
in the presence of EGF. 
Fluorescent flow cytometry analysis of binding of the selected anti-EGFR clones to rhEGFR-Fc in the 
presence or absence of EGF. Histograms show the fluorescence intensity of bacteria incubated with 
biotinylated rhEGFR (50 nM) in the presence or absence of 25 µM EGF.   
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In this thesis, we have evaluated and described the application of two β-domains of 
EhaA and Intimin from EHEC, for the surface display of VHH clones and immune 
libraries against 3 different antigens of biomedical importance i.e. the extracellular 
domain of the translocated intimin receptor from EHEC (TirMEHEC), human 
fibrinogen (Fib) and epidermal growth factor receptor (EGFR). The anti-TirMEHEC and 
anti-Fib VHH libraries were initially used to setup the selection conditions by MACS 
and to compare the effectiveness of the two β-domains in selection of VHH thereof. 
Further, the more effective β-domain from Intimin was used to display an immune 
library raised using tumor cells overexpressing hEGFR and select specific high 
affinity binders against hEGFR using the recombinant extracellular domain of 
hEGFR fused to Fc and murine tumor cell lines transfected with or without hEGFR. 
 
We have found that the β-domains of EhaA and Intimin are effective platforms for 
the surface display of VHH libraries on E. coli K-12 cells, and allow for selection of 
high affinity VHHs from immune libraries using biotinylated antigen and MACS 
(Salema et al., 2013). Despite their opposite topologies, both systems express 
stable fusion proteins with the native β-barrel properly folded in the OM and the VHH 
domain displayed to the extracellular mileu, retaining functionality and antigen 
binding capacity. Most clones in the immune libraries were displayed at good levels 
on E. coli with both EhaA and Intimin β-domains, with an average of 6000-8000 
molecules/bacterium. From each of the immune libraries used in our studies, we 
obtained about 3-6 different camelid VHH sequences with different binding affinities 
(in the nM range) to the antigen used in the immunization, which is one of the 
advantages of using immune libraries. These results demonstrate that both the E. 
coli display systems can be used to retrieve high-affinity binders from immune 
libraries of VHH sequences. The small molecular weight, high protein solubility and 
stability of camelid VHH domains are likely to aid their effective translocation across 
the OM  fused to the β-domains of either EhaA and Intimin. Similar properties have 
been reported with other natural sdAbs, like VNARs from sharks (Dooley, 2003), 
which have been engineered in synthetic libraries based on human VHs and VLs. 
Thus, it is likely that other types of sdAbs could also be efficiently displayed on E. 
coli cells with the EhaA and Intimin β-domains. Display of larger rAb fragments 
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based on a single polypeptide such as scFvs could be also possible, although the 
tendency to aggregate of many scFv molecules may difficult their translocation 
across the OM (Veiga et al., 2004). Nevertheless, this could be advantageous for the 
selection of highly stable and soluble scFvs from libraries. Lastly, Ab molecules with 
separate H and L polypeptide chains (e.g Fabs, IgGs) cannot be displayed with 
these β-domains (atleast in their current conformation), and either phage display or 
APEx (Harvey et al., 2004; Mazor et al., 2007; Mazor et al., 2010) should be used 
instead for their selection in E. coli. 
 
Comparison of EhaA and Intimin display systems led to the observation of some 
important differences between them. Firstly, NVHH fusions were found to be more 
stable than VHHA fusions in vivo (to E. coli proteases) and in vitro (to externally 
added proteases), which could be attributed to the natural resistance of Intimin to 
proteolysis and denaturation (Bodelon et al., 2009); and/or due to the susceptibility 
of certain ATs to endogenous bacterial proteases as a part of their secretion 
mechanism (Bernstein, 2007; Leyton et al., 2012b). Secondly, expression of VHHA 
clones appeared to be more variable than NVHH fusions, with some clones showing 
significantly lower expression levels. This suggests that the N-terminal fragment of 
Intimin could have a positive effect on the expression of VHHs, as observed with 
other N-terminal fusion partners (i.e. MBP, Trx1, GST) used routinely for the 
production of recombinant proteins and Ab fragments (Jurado et al., 2006). Thirdly, 
the antigen binding levels determined by flow cytometry with NVHH library were 
found to be atleast 3 fold higher than the respective VHHA library. The lower antigen 
binding signals of E. coli cells displaying VHHA fusions could not be solely attributed 
to lower expression levels, and indicated the existence of additional factors. 
Eventhough partial misfolding of VHHA fusions cannot be totally excluded, this 
seems unlikely given that both EhaA and Intimin β-domains use a common 
secretion pathway, exposing the VHHs to the same periplasmic folding factors (e.g. 
DsbA) and chaperones (e.g. FkpA and Skp) that are known to participate in the 
folding of Ig domains (Bodelon et al., 2012). An alternative explanation could be that 
the longer linker region in NVHH fusions (with the D0 domain), could make the VHH 
domain more accessible for binding to the antigen in solution by increasing its 
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distance from the OM. The improved stability, higher expression levels and superior 
antigen binding activity could explain the reason why selection of high affinity 
binders from the anti-TirMEHEC and anti-Fib libraries was more efficient using the 
Intimin system than the EhaA system, with a higher percentage of positive antigen-
binding clones being achieved in fewer selection rounds. The superior antigen 
binding signals with the Intimin β-domain also facilitates the estimation of the affinity 
of the selected NVHH clones to their antigen by flow cytometry. From our data, the 
only possible limitation of Intimin display could be a slight decrease in the viability of 
E. coli cultures expressing some NVHH fusions, which was observed for anti-
TirMEHEC library. However, this reduction in viability of NVHH was not observed 
during the expression of anti-Fib library. We have recently tested the viability of  
anti-EGFR library (data not shown), and found that the viability is not affected, being 
~0.9x109 CFU/OD600. Hence, some specific attributes of the anti-TirMEHEC library 
could cause the observed toxicity in NVHH fusions. In any case, the observed 
reduction does not have a significant effect on the representation of immune 
libraries with a diversity of ∼107 clones, since an excess of input bacteria over the 
library size is always used during MACS (≥108 bacteria). 
 
The number of antigen-specific high affinity binders obtained from each immune 
library could be more connected to attributes of the library itself, such as the 
immunogenicity of antigen, number of animals used in the immunization, or size and 
complexity of the library  (Bradbury and Marks, 2004), rather than on the 
effectiveness of the surface display system used for selection. In the case of the 
anti-TirMEHEC library, we obtained a single high affinity binder i.e. VTIR1 and four other 
binders i.e. VTIR2 to VTIR5, of lower affinities. However, previous selection of the 
same anti-TirMEHEC library by phage display had failed to retreive specific high-
affinity binders other than VTIR1 isolated by E. coli display (data not shown). 
Similarly, selections of the anti-Fib and anti-EGFR libraries using E. coli display led 
to identification of a similar number of high affinity binders and essentially the same 
clones that were also isolated by phage display of these VHH libraries (Roovers et 
al., 2007); and data not shown. Thus, it appears that the actual diversity of binders 
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retreived from immune libraries is more dependent on intrinsic factors of the library 
rather than on the display system used for selection. 
 
Abs are in huge demand for use in diagnosis and therapy and so is the need for 
inexpensive Ab expression systems for their selection and production. E. coli is an 
attractive expression system since it requires inexpensive media, has fast growing 
times, high efficiency of transformation (>1010 transformants/µg of plasmid DNA), 
well-characterized, versatile cloning and expression vectors. Although the 
purification of Nbs from the periplasm of E. coli is relatively straightforward owing to 
their high solubility and simplicity in structure, variable yields are commonly 
obtained among different clones (e.g. 0.1-0.5 mg/L of induced culture for Nbs). To 
alleviate this issue and increase the total yield of Nb produced, we investigated their 
production fused to the periplasmic maltose binding protein (MBP) of E. coli. In 
addition, we included a His6 tag in the C-terminus of the fusions to allow the use of 
a double affinity chromatography during the  purification, with amylose and 
immobilized metal resins. Expression of the constructs in standard E. coli strains 
such as BL21 resulted in high levels of proteolysis, and so an E. coli strain deficient 
in periplasmic proteases i.e. HM140 was used. Soluble MBP-VHHHis6 fusions were 
consistently expressed at high levels (>12 mg/L of induced culture) in the periplasm 
of E. coli. Highly pure MBP-VHHHis6 fusions  were recovered by amylose and 
immobilized metal affinity chromatography steps. Good yields of soluble VHHHis6  
(between 2-3 mg/L of induced culture) were obtained after site-specific proteolysis 
of the fusions and their monomeric nature was confirmed by gel filtration. Both, 
MBP-VHHHis6 fusions and free VHHHis6 retained antigen binding activity and specificity 
(Salema and Fernandez, 2013). The anti-Fib VHH, i.e. VFIB1 purified in this manner 
was successfully applied in the development of a disposable 
magnetoimmunosensor for detection of fibrinogen in plasma (Campuzano et al., 
2014). 
 
We chose MACS to select and recover E. coli cells bound to the antigen since this 
technology does not require expensive equipment like the fluorescent cell sorter 
used in FACS, and multiple samples can be processed in parallel. While we used a 
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manual MACS system (holding upto 8 mini-MACS columns, each with a capacity of 
∼108 bacteria), MACS is easily scalable to columns with higher loading and 
capturing capacities, with the possibility of being automated, thus making screening 
of large Ab libraries faster and more efficient than FACS.  
 
Although MACS is an easy and fast way to select high affinity binders from an Ab 
library, this method relies on the availability of purified antigen, which is not always 
practical or feasible. Direct selection on cells expressing the antigen(s) of interest 
maybe required when an antigen is produced at low yields, has low solubility, or 
does not maintain its native conformation upon purification. It may also be an 
attractive approach to identify Abs against unknown antigens expressed on the 
surface of target cells (Ahmadvand et al., 2009; Pavoni et al., 2014).  This may be 
challenging for antigens with low levels of expression, but it is clearly realistic with 
surface antigens overexpressed under certain conditions (e.g. tumor cells). In our 
work we used an anti-EGFR library that was obtained by immunizing llamas with 
whole A431 cells (EGFR+) (Roovers et al., 2007). This library was cloned into the 
Intimin system and selected directly on cells using a combination of negative 
selection cycles on cells that did not express EGFR (NIH-3T3 2.2) and positive 
selection cycle on cells expressing EGFR (HER14). The selection was very effective 
and we were able to enrich the anti-EGFR libraries in just two rounds of selection on 
cells. Out of the CellS, we obtained four specific binders with good affinities to 
EGFR (one of which was specific to this method of selection), as validated by flow 
cytometry analysis of binding to these clones to recombinant EGFR antigen and 
BSA (control). All these clones also bound specifically to HER14 cells but not to 
NIH-3T3 2.2 cells and competed with EGF for binding to EGFR at different levels (as 
demonstrated in flow cytometry assays). Further, the KD of the two best clones (i.e 
VEGFR1 and VEGFR2) was estimated by flow cytometry and was found to be 30 nM 
and 12 nM respectively. 
 
In this work we have demonstrated that E. coli display is suitable for use with 
immune libraries with 106-107 clones.  Nonetheless, this method is not limited to 
these types of libraries and could also be used with larger naïve and synthetic 
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libraries of ∼109 clones (Arbabi-Ghahroudi et al., 2009; Monegal et al., 2009; 
Hussack et al., 2012).  As mentioned previously, MACS can be scaled up with larger 
columns than those used in our work, hence allowing the screening of ~5x109 
bacteria/column. Several of these MACS columns of large capacity can be run in 
parallel covering the total diversity of libraries ∼109-1010 clones.   In these type of 
MACS columns, larger volumes and densities of E. coli bacteria can be loaded. 
Importantly,  E. coli can be manipulated with ease at a density of is ~1x1010 CFU/ml, 
which  is similar to the maximum size of most naïve and synthetic libraries of Ab 
fragments. . For large naïve and synthetic Ab libraries, phage display may appear to 
be more advantageous than E. coli display, given that bacteriophages can be 
produced and handled in higher densities than E. coli  (i.e. 1013 PFU/ml). However, 
the diversity of phage display libraries is also strongly limited by intrinsic E. coli 
factors like transformation efficiency and the ability of phages to infect cultures with 
sufficient amount of bacteria. In addition, the percentage of phage particles actually 
displaying at least a single Ab molecule on the surface could be as low as less than 
10% of the total infecting particles when conventional helper phages with wild type 
pIII (e.g. M13K07) are used to rescue phagemids (Rondot et al., 2001; Oh et al., 
2007; Soltes et al., 2007). Hence, the actual density of phage-antibody particles is 
likely to be atleast one order of magnitude lower than the titer of phage solutions 
and the actual number of clones is limited by E. coli transformation, efficiency, as it 
happens with E. coli display. Therefore, E. coli display and phage display libraries 
are appropriate for libraries containing ∼109-1010 different clones. Screening of 
larger Ab libraries with higher diversities will require the use of cell-free display 
systems (e.g. ribosome display) that avoid transformation of plasmid vectors to E. 
coli (Pluckthun, 2012; Sun et al., 2012; Kanamori et al., 2014). 
 
One of the major benefits of E. coli display over phage display is the use of flow 
cytometry for the direct determination of the expression levels, antigen-binding 
specificity and affinity of the selected clones. In addition, eventhough E. coli cells 
are more sensitive than bacteriophages to extremes of pH, temperature and other 
strong denaturants, E. coli bacteria having their OM intact can be washed with most 
common buffers as well as tolerate significant concentrations of detergents (e.g. 
Discussion 
  126 
0.1-0.4% w/v of TX-100, SDS or deoxycholate) marking an improvement over the 
washing conditions tolerated by spheroplasts in APEx. The multivalent Ab display 
and the less sticky properties of E. coli cells compared to bacteriophages makes 
selections to complex antigenic surfaces e.g. mammalian cells, tissues and organs, 
with reduced background binding possible. 
 
We have envisaged some putative biomedical applications for the antigen-specific 
high affinity VHHs selected from the each of the different VHH libraries. The VHH 
against TirMEHEC, i.e. VTIR1 is a high affinity binder and has a very slow rate of 
dissociation. Such a binder could be useful in recognization and binding to Tir, thus 
preventing the association of EHEC to the intestinal surface and further 
pathogenesis of the bacteria. The VHHs against Fib can be used for diagnostic 
applications such as detection of fibrinogen levels in the blood using ELISA or other 
detection methods. In this regard, we have used VFIB1 in electrochemical biosensor 
for the measurement of fibrinogen levels in the blood plasma (Campuzano et al., 
2014). Finally, the VHHs against human EGFR need further evaluation of their ability 
to compete and block the EGFR binding of natural ligands such as EGF, TGF-α etc, 
thus mimicking the mode of action of some mAbs currently in therapy e.g. Erbitux 
or Vectibix. This would result in the switching off of signal transduction cascades 
that lead to uncontrolled growth and proliferation of cells, as occurring in cancer.              
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The following are the conclusions of the doctoral thesis: 
 
1. The E. coli display systems based on the β-domains of Intimin and EhaA from 
EHEC represent a good alternative to phage display and other cell display platforms 
(e.g yeast display), for the selection of high affinity sdAb binders from immune 
libraries of VHHs. The ability to display and select sdAbs without the need for 
permeabilization of the OM, along with the lower toxicity of the Neae, EhaA fusions 
are advantages of the two β-domains tested over other existing E. coli display 
formats. 
 
2. E. coli bacteria displaying two different VHH libraries (obtained after immunization 
with TirMEHEC or Fib antigens) using both β-domains, were successfully screened 
with their respective biotinylated antigens using MACS, and facilitated the isolation 
of specific binders with high affinity against TirMEHEC and Fib. These studies also 
revealed that E. coli display with the Intimin β-domain is a more effective platform 
for selection of binders in fewer rounds. In addition, E. coli bacteria displaying VHHs 
with Intimin β-domain have higher antigen-binding signals in flow cytometry. 
 
3. Flow cytometry of E. coli bacteria displaying VHH clones and libraries was used 
for direct determination of the expression levels, antigen binding specificity and 
affinity of the selected sdAbs by flow cytometry, representing a major benefit of E. 
coli display. Apparent KD values determined by flow cytometry of E. coli bacteria 
displaying sdAbs  against TirMEHEC and Fib were very similar to those obtained with 
the purified sdAbs and state-of-the-art technologies such as SPR. 
 
4. The multivalent nature of E. coli display and the less sticky properties of E. coli 
cells compared to filamentous bacteriophages, reduces background and non-
specific binding and, thus makes E. coli display an optimal platform for  selections 
not only with purified antigens but also on complex antigenic surfaces and cells 
(e.g.  tumor cells) . High-affinity sdAbs binding human EGFR were selected from an 
E. coli display library of VHHs generated by immunization of llamas with human 
tumor cells overexpressing EGFR i.e. A431, using selections with either a 
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recombinant extracellular domain of hEGFR or murine tumor cell lines transfected 
with hEGFR. 
 
5. Soluble sdAbs can be purified in high amounts from the periplasm of E. coli  
strain HM140 as N-terminal fusions to MBP. MBP-VHH fusions bind their cognate 
antigen specifically and allow purification of the soluble VHH moiety with a C-
terminal His-tag after cleavage of the fusion with a site-specific protease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
  132 
Del trabajo presentado en esta tesis podemos obtener las siguentes conclusiones: 
 
1. Los sistemas de presentación de sdAbs basados en los dominios β de 
intimina y EhaA de EHEC representan una buena alternativa a la 
presentación en fagos y otras plataformas de presentación en células (por 
ejemplo la presentación en levaduras), para la selección de sdAbs con alta 
afinidad por antígeno a partir de genotecas inmunes de VHHs. La capacidad 
de exponer y seleccionar sdAbs sin la necesidad de permeabilizar la OM, 
junto con la baja toxicidad de las fusiones con Neae (intimina) o con EhaA 
son ventajas de estos sistemas en relación a otros formatos de 
presentación de sdAbs en E. coli actualmente existentes. 
 
2. Se han seleccionado con éxito clones de alta afinidad a antígenos 
específicos desde genotecas de sdAbs presentados en la superficie de 
bacterias E. coli. Dos genotecas de VHH diferentes (obtenidas después de 
inmunizaciones con los antígenos TirMEHEC o Fib) se presentaron en la 
superficie de E. coli con  ambos dominios β y fueron rastreadas mediante 
MACS con sus respectivos antígenos marcados con biotina para 
seleccionar clones que se unían específicamente y con gran afinidad a 
estos antígenos. Estos estudios también revelaron que el sistema de 
presentación con el dominio β de la intimina es una plataforma más eficaz 
para el aislamiento de clones específicos realizando pocas rondas de 
selección. Asimismo, las bacterias E. coli que presentaban VHHs con el 
dominio β de la intimina presentan señales de fluorescencia más elevadas 
en los análisis por citometría de flujo. 
 
3. Hemos utilizado la técnica de citometría de flujo con bacterias E. coli que 
presentaban clones de VHH individuales y colecciones de VHH para la 
determinación directa de los niveles de expresión de los VHHs, la 
especificidad de unión al antígeno y la afinidad de los sdAbs seleccionados, 
lo que representa una ventaja importante de los sistemas de presentación 
de sdAbs en E. coli. Los valores de KD estimados mediante análisis por 
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citometría de flujo de bacterias E. coli que presentan sdAbs frente a TirMEHEC 
y Fib fueron muy similares a los valores obtenidos con sdAbs purificados 
aplicando tecnologías de última generación como SPR. 
 
4. La naturaleza multivalente de la presentación de sdAbs en E. coli y la  
tendencia menor a adherirse inespecíficamente de las células de E. coli en 
comparación con bacteriófagos filamentosos, reduce la probablidad de 
obtener clones inespecíficos. Por ello, la presentación de sdAbs en E. coli 
es una plataforma óptima para la selección de clones específicos, no sólo 
utilizando antígenos purificados sino también sobre superficies 
antigénicamente complejas y células (ej. células tumorales). Hemos 
seleccionado sdAbs de afinidad frente al EGFR humano a partir de una 
genoteca de sdAbs presentada en E. coli y generada mediante 
inmunización con células tumorales humanas que sobreexpresaban EGFR 
(ej. A431). Las selecciones se realizaron con éxito utilizando tanto un 
dominio extracelular de EGFR humano y una línea celular murina 
transfectada con EGFR humano. 
 
5. Los sdAbs pueden ser purificados en grandes cantidades y de forma 
soluble como fusiones amino terminal a MBP producidas en el periplasma 
de la cepa de E. coli HM140 deficiente en proteasas periplásmicas. Las 
fusiones MBP-VHH se unen específicamente a sus antígenos respectivos y 
permiten la purificación del dominio VHH con una cola de histidinas (His6) en 
su extremo C-terminal, tras la escisión de la MBP utilizando una proteasa 
específica de sitio. 
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